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SUMMARY 
Vernonia amygdalina (VA) is well-known for its medicinal importance and it is used 
in Nigeria, Ghana, and South Africa for the treatment of diabetes. A dose-response 
study was conducted to determine the optimum dose for the hypoglycemic effect of 
VA in streptozotocin (STZ)-induced diabetic rats. The optimum dose (400 mg/kg) 
was used throughout the 28-day chronic study. Body weight, food and water intakes 
of the rats were monitored daily. Fasting blood serum, pancreas, liver and soleus 
muscle were collected for biochemical analyses. Chemical composition of VA was 
analysed using high-performance liquid chromatography (HPLC) and liquid 
chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). In an oral 
glucose tolerance test, 400 mg/kg VA exhibited a significant improvement in glucose 
tolerance of the STZ-induced diabetic rats. 28-day treatment with 400 mg/kg VA 
resulted in decrease in fasting blood glucose compared to diabetic control. VA also 
caused significant decrease in triglyceride and total cholesterol levels. Furthermore, 
VA was found to increase expression of GLUT 4 in rat skeletal muscle. Further tissue 
fractionation revealed that it can increase the GLUT 4 translocation to plasma 
membrane as well, suggesting that VA may stimulate skeletal muscle’s glucose 
uptake. This observation is in line with the restoration in skeletal muscle glycogenesis 
of VA-treated group. In addition, VA also suppressed glucose-6-phosphatase 
(G6Pase). Hence, VA possesses antihyperglycemic effect, most probably through 
increasing GLUT 4 translocation and inhibiting hepatic G6Pase. 1,5-dicaffeoyl-quinic 
acid, dicaffeoyl quinic acid, chlorogenic acid and luteolin-7-O-glucoside in the extract 
may be the candidates that are responsible for the above-mentioned biological 
activities. 
ix 
    
Besides VA, coffee also contains high levels of chlorogenic acid (CGA). Regular 
consumption of coffee has been associated with a lower risk of Type 2 diabetes 
mellitus (T2DM) but these beneficial effects cannot be explained by caffeine. 
Moreover, CGA has been shown to delay intestinal glucose absorption and thus 
suppressing postprandial glucose levels. On the other hand, improvement in fasting 
glucose and insulin cannot be explained by the delay in intestinal glucose absorption. 
Therefore, the present author  next studied its effect on other metabolic pathways and 
likewise its effects after long-term consumption. He investigated the effects of CGA 
on glucose tolerance, insulin sensitivity, hepatic gluconeogenesis, lipid metabolism 
and skeletal muscle glucose uptake in Lepr
db/db
 mice. Hepatoma HepG2 was used to 
investigate CGA’s effect on hepatic glucose production and fatty acid synthesis while 
L6 myotubes was used to further strengthen our findings in animal skeletal muscles. 
Subsequently, he attempted to evaluate whether these effects of CGA are associated 
with the activation of AMPK. In Lepr
db/db
 mice, acute treatment with CGA lowered 
AUCglucose in an OGTT. Chronic administration of CGA inhibited hepatic G6Pase 
expression and activity, attenuated hepatic steatosis, improved lipid profiles and 
skeletal muscle glucose uptake, which in turn improved fasting glucose level, glucose 
tolerance, insulin sensitivity and dyslipidemia in Lepr
db/db
 mice. CGA activated 
CAMKK and AMPK, leading to subsequent beneficial metabolic outcomes, such as 
suppression of hepatic glucose production, fatty acid synthesis and glucose uptake in 
skeletal muscles. Inhibition and knockdown of AMPK and CAMKK abrogated these 
metabolic alterations. In conclusion, CGA improved glucose and lipid metabolism, 
via the CAMKK-dependent activation of AMPK. All these suggest that CGA could 
be the main component that contributes to the beneficial effects of VA and coffee and 
also the paradoxical effect of coffee in T2DM.
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1 Chapter 1: Introduction 
 
1.1 Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting 
from defects in insulin secretion, tissues sensitivity to insulin or both. Hyperglycemia 
is usually accompanied by symptoms which include polyuria, polydypsia, polyphagia 
and at times blurred vision. Chronic hyperglycemia results in complications such as 
retinopathy with potential loss of vision, nephropathy which leads to renal failure, 
neuropathy and other cardiovascular disorders. There are three criteria to make a 
diagnosis of diabetes, which are elevated fasting blood glucose, abnormal oral glucose 
tolerance test and symptoms of diabetes with hyperglycemia (Appendix 1). 
Previously, the use of glycated-hemoglobin (A1C) for the diagnosis of diabetes was 
not recommended due the lack of uniformity in the assays worldwide [1]. However, 
A1C assays are now highly standardized so their results now can be uniformly applied 
both temporally and across populations [2]. The A1C value of ≥6.5% is used as a 
diagnostic threshold. However, the diagnostic test should be performed using a 
method that is certified by the National Glycohemoglobin Standardization Program 
(NGSP) and standardized or traceable to the Diabetes Control and Complications 
Trial reference assay. 
In 2000, the estimated prevalence of diabetes among adults was 2.8% or 171 million 
people and it is expected to increase to 4.4% or 366 million people by the year of 
2030 [3] (Appendix 2). This growing burden of diabetes will lead to global financial 
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burden and also indirect cost to society, which is the health status of human 
population.  
1.2 Classification of Diabetes Mellitus 
Diabetes can be categorized into two major categories known as Type 1 diabetes 
mellitus (T1DM) and T2DM. T1DM is often genetically-associated and immune-
mediated. Individuals with T1DM have an absolute deficiency in insulin secretion and 
can be identified by serological evidence of autoimmune-mediated destruction of 
pancreatic islets or by genetic markers. However, this form of diabetes only accounts 
for 5-10% of those with diabetes. Also known as juvenile-onset diabetes, the rate of 
β-cells destruction in this form of diabetes is usually rapid in infants and children. 
However, it can occur at any age, even as late as eighties or nineties in life. Markers 
responsible for this destruction include islet cell autoantibodies (ICAs), insulin 
autoantibodies (IAAs), glutamic acid decarboxylase autoantibodies (GAD65), and 
autoantibodies to tyrosine phosphatase IA-2 and IA-2α [4-7]. One and more of these 
autoantibodies are present in 85-90% of individuals when fasting hyperglycemia is 
initially detected. There is another form of T1DM where the pathogenicity is less well 
understood and hence known as idiopathic diabetes. Individuals in this category 
usually have permanent insulinopenia but lack signs of autoimmunity. This form of 
diabetes is strongly inherited. Hormone replacement therapy is not absolutely 
necessary for survival in this case as the degree of β-cell dysfunction varies among 
individuals [8]. 
The most common type of diabetes, T2DM, accounts for 90-95% of those with 
diabetes. Individuals in this category can either have predominant insulin resistance 
with relative insulin deficiency or predominant insulin secretory defect with insulin 
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resistance. The etiology of this form of diabetes is wide and complicated, ranging 
from abnormalities in lipoprotein metabolism, central or visceral obesity, to 
cardiovascular risk factors such as hypertension. However, pancreatic islets 
destruction does not occur in T2DM. On the contrary, insulin resistance may cause 
patient to have normal or even higher level of insulin. This form of diabetes is always 
associated with obesity. It’s becoming more common in developed and developing 
countries, afflicting younger generations victimized by a global epidemic of 
overweight and obesity [9]. 
There is another type of diabetes diagnosed during pregnancy named gestational 
diabetes. Most of the cases resolve with delivery, but the condition may persist in 
some cases as unrecognized glucose intolerance may have begun before the 
pregnancy. Evaluation of gestational diabetes should be done early in the pregnancy 
except for those in low risk group, who  
 Are less than 25 years old 
 Have a normal BMI 
 Have no family history of diabetes 
 Have no history of abnormal glucose metabolism 
 Have no history of poor obstetric outcome 
 Are not members of an ethnic/racial group with a high prevalence of diabetes 
such as Hispanic Americanw, Native Americans, African-Americans, and 
Pacific Islanders  
4 
    
Study has shown that gestational diabetes was associated with poor maternal and fetal 
outcomes [10]. 
1.3 Normal Glucose Homeostasis 
Plasma glucose is maintained at a rather consistent value of approximately 90 mg/dl 
(5 mmol/l), with a maximal increase of not exceeding 165 mg/dl (9.2 mmol/l) after a 
meal [11] or a decrease down to not lower than 55 mg/dl (3.1 mmol/l) after exercise 
[12] or a moderate 60-hour fast [13]. Glucose can be from dietary source or is either 
from the gluconeogenesis in liver and kidney or the breakdown of glycogen 
(glycogenolysis) in liver. This glucose may be stored directly as glycogen through the 
process of glycogenesis in liver or may undergo glycolysis, which can be non-
oxidative, producing pyruvate or oxidative, through oxidization of acetyl CoA to 
carbon dioxide and water in the tricarboxylic acid cycle or commonly known as Krebs 
cycle (Figure 1.1). 








    
They are several key regulators that regulate glucose homeostasis: 
I. Insulin 
This major regulator affects glucose metabolism both directly and indirectly. 
Its receptors are available in insulin-sensitive organs such as liver, kidney, 
muscle and adipose tissue. Activation of insulin signaling upon binding of 
insulin to insulin receptors causes suppression of gluconeogenesis in liver and 
kidney [14], translocation of glucose transporter-4 (GLUT 4) from inner 
membranes to plasma membrane in liver, muscles and adipose tissue to 
increase glucose uptake [15], and inhibition of free fatty acid release into 
circulation [16]. As free fatty acid stimulates gluconeogenesis and reduce 
glucose transport into cells, release of insulin also indirectly regulates 
gluconeogenesis and glucose transport through free fatty acids. Besides, 
insulin promotes glycogen synthesis by inhibiting glucose-6-phosphatase 
(G6Pase) and glycogen phosphorylase while stimulating glycogen synthase 
[17]. Increased plasma glucose results in increase in plasma insulin while 
decrease in plasma glucose causes reduction in plasma insulin level as well. 
II. Glucagon 
Unlike insulin secreted from pancreatic β cells, glucagon is secreted from α-
cells of the pancreas. Glucagon secretion is stimulated by hypoglycemia 
whereas hyperglycemia will inhibit its secretion. Glucagon acts exclusively on 
liver by activating glycogen phosphorylase and results in immediate glucose 
release [18]. Further action of glucagon will be through stimulation of 
gluconeogenesis [19]. 
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III. Catecholamines 
Catecholamines are molecules that act as both hormone, in blood circulation 
and neuromodulator, in central nervous system. During stress and 
hypoglycemia catechoamines are released and they inhibit insulin secretion 
and action. In the liver, through β2-adrenergic receptors, they activate 
glycogen phosphorylase and augment gluconegenesis [20]. In the kidney, they 
are potent stimulators of gluconegenesis. In skeletal muscle, they reduce 
glucose uptake and stimulate glycogenolysis. They also activate lipase and 
result in lypolysis in adipose tissue to increase release of free fatty acid [21]. 
IV. Growth Hormone and Cortisol 
Both metabolic actions of growth hormone and cortisol are antagonistic to 
those of insulin. These include increase secretion of gluconeogenic enzymes, 
reduce glucose transport and inhibit lipolysis [22, 23]. In addition, cortisol also 
impairs insulin secretion and therefore further debilitating insulin signaling. 
V. Free Fatty Acids 
As mentioned before, increased plasma free fatty acids will result in 
stimulation of renal and hepatic gluconeogenesis, inhibition of glucose 
transport in muscles and adipose tissue and competition with glucose as 
metabolic fuel [24]. 
VI. Incretins 
Incretins are hormones secreted by intestine in response to nutrients ingestion. 
Their main effect is to stimulate pancreas to release insulin after meals intake. 
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Two incretin hormones were identified so far: gastric inhibitory polypeptide 
(GIP) and glucagon-like peptide-1 (GLP1). Both of them have short half-life 
due to rapid digestion by proteolytic enzyme known dipeptidyl peptidase-4 
(DPP-4). 
1.4 Insulin signaling vs AMPK-dependent pathway 
The insulin signaling and AMP-activated protein kinase (AMPK)-dependent 
pathways regulate glucose and fatty acid metabolism, cellular growth, differentiation 
and survival in various eukaryotic tissues [25, 26]. Activation of insulin signaling is 
an anabolic process while AMPK activates catabolic pathways to conserve energy. 
Signal transduction from the stimulus to the regulation of various cellular processes 
usually involves protein kinase signaling. Insulin signaling is initiated upon the 
binding of the hormone to its receptor which triggers the conformational changes and 
autophosphorylation of the tyrosine residues. Activated insulin receptor attracts 
insulin receptor substrates and tyrosine phosphorylates them. Once activated, insulin 
receptor substrates recruit downstream molecules such as phosphatidylinositol 3-
kinase (PI3K), Cbl-associated protein (CAP) and protein kinase C (PKC), which are 
the major conduits for GLUT 4 recruitment and glucose regulation. 
AMPK, a sensor of intracellular energy, is activated at low cellular energy levels and 
regulates cellular processes accordingly. Physiological or pathophysiological stimuli 
such as hypoxia, muscle contraction, oxidative stress and glucose deprivation cause 
an increase in AMP/ATP ratio, which is crucial for AMPK activation [27]. The 
activity of AMPK is also modulated by hormones and cytokines that affect whole-
body energy balance, and by insulin sensitizers like thiazolidinediones [28]. Also, the 
effect of the widely used antidiabetic drug metformin have been shown to depend 
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largely on AMPK activation [29]. Other kinases such as liver kinase B1(LKB-1) and 
calcium/calmodulin-dependent protein kinase kinase β (CAMKKβ) have been shown 
to be the upstream kinases that phosphorylate AMPK. AMPK regulates glucose 
homeostasis by increasing glucose uptake in peripheral tissues and glycolysis 
independently of insulin [30]. In addition, AMPK regulates hepatic glucose output by 
inhibiting expression and activity of hepatic gluconeogenic enzyme, G6Pase [31]. 
AMPK also enhances fatty acid transport and oxidation, while switching off fatty acid, 
cholesterol and glycogen synthesis and therefore resulting in its insulin sensitizing 
properties [32].  
 
1.5 Pathogenesis of T2DM 
Although T2DM makes up most cases of diabetes mellitus, its pathogenesis remains 
unclear, most probably due to its heterogeneity. Two main factors account for the 
development of T2DM, which are the genetic factors and the environmental 
influences. Studies have shown that most patients have a positive family history and 
the risk for developing T2DM is increased up to 40% by having a first-degree relative 
with the disease [33]. Environmental factors such as physical inactivity, obesity and 
dietary habits may interact with genetic factors and increase the risk of developing 
diabetes.  
1.5.1 β-cell Dysfunction 
Compared to normoglycemic subjects, impaired glucose tolerance (IGT) subjects 
secrete less insulin at any given glucose level [34]. Islet β-cells function declines 
progressively from IGT to complete glucose intolerance (CGI) which appears to be 
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the reason why patients who are initially well controlled by a single oral 
hypoglycemic agent require increasing dose or combined agents to maintain glycemic 
indices [35]. There are several possible causes that result in β-cells dysfunction. 
Glucotoxicity and lipotoxicity are conditions where islet β-cells are exposed to high 
glucose or free fatty acids levels chronically. Long-term exposure to high glucose and 
free fatty acid levels impair insulin secretion from β-cells [36, 37]. Human islet 
amyloid polypeptide, IAPP or amylin, is normally co-localized within the same 
secretory vesicles as insulin [38] and co-released with insulin in response to glucose 
or non-glucose secretagogues [39]. Deceased IAPP release but increased islet amyloid 
deposit  have always been found in T2DM [40] and amyloid deposition has been 
proposed to decrease β-cell mass [41]. 
1.5.2 Insulin Resistance 
Instead of impaired insulin secretion, in some T2DM patients, hyperinsulinemia 
coexists with hyperglycemia, which is commonly associated with obesity and insulin 
resistance [42]. By using hyperinsulinemic-euglycemic clamp technique, obese and 
diabetic patients have been correlated to decreased responsiveness or diminished 
sensitivity in insulin-stimulated whole-body glucose disposal [43]. Reduced numbers 
of insulin receptors, impairments in insulin receptor substrate and PI3K are primarily 
related to insulin resistance. Besides genetic factor, acquired insulin resistance gains 
much attention for the prevention and progression of the disease. Owing to 
dyslipidemia in obese patients, elevated free fatty acid levels are associated with non-
alcoholic hepatic steatosis [44], insulin resistance [45], decrease in skeletal muscle 
glucose disposal [46] and increased hepatic glucose production [47]. Apart from 
decreasing β-cell function, chronic physiological increment in the plasma glucose 
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concentration also leads to progressive insulin resistance in T2DM [48]. However, to 
date, it is still unclear with regard to the relative contributions of pancreatic β-cell 
dysfunction and insulin resistance to the pathogenesis of T2DM. 
1.5.3 Fasting Hyperglycemia vs Postprandial Hyperglycemia 
In post-absorptive state, majority (65-70%) of glucose uptake occurs in insulin-
insensitive tissues such as brain, erythrocytes and splanchnic tissues and glucose 
uptake is precisely matched by the rate of hepatic glucose production [49]. Therefore, 
gluconeogenesis is the main source of fasting glucose elevation [50] and is regulated 
primarily by insulin and glucagon [51]. In the condition of insulin resistance or 
impaired insulin secretion, glucose uptake cannot increase appropriately in response 
to hepatic glucose output. As a result, small increases in glucose production cause 
proportional increase in fasting glucose level. 
Following glucose ingestion, increase in plasma glucose stimulates insulin secretion, 
which in turn suppresses hepatic glucose production and stimulates glucose uptake by 
peripheral tissues (50-60% of glucose uptake is by skeletal muscles) to restore 
normoglycemia [52]. Several factors contribute to postprandial hyperglycemia in 
T2DM. First, the total amount of glucose entering the systemic circulation is 
increased due to the insufficient suppression of hepatic glucose output during fasting 
or post-absorptive state, as discussed above [53]. Second, the efficiency of glucose 
disposal is reduced because of insulin resistance in peripherals, especially skeletal 
muscles, and relative or absolute insulin deficiency [54]. Third, hepatic glucose 
uptake is impaired, although this defect makes a relatively small contribution since 
the liver normally takes up only 20-35% of a glucose load [55]. 
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1.6 Management of T2DM 
Management of diabetes and maintaining near-normal plasma glucose levels are of 
utmost importance in order to prevent the development of diabetic complications such 
as nephropathy, neuropathy, retinopathy, dyslipidemia and cardiovascular diseases, 
which are comparatively more lethal. A number of therapeutic choices are available 
for the management of the disease; however, none are free of disadvantages. 
Pharmacological intervention remains the most effective way to control plasma 
glucose level but it is always associated with unwanted side effects.  Sulfonylureas 
initiate insulin release even when glucose level is low [56] and therefore are more 
likely to cause hypoglycemia [57]. Besides, as sulfonylureas stimulate insulin 
secretion, their effective use requires significant residual β-cell function [58]. Efficacy 
is better in patients shortly after diagnosis of T2DM when most β-cell function is still 
preserved [59]. Thiazolidinediones often cause weight gain which will further 
deteriorate insulin resistance [60] and increase cardiovascular mortality risk e.g. 
pioglitazone [61, 62]. The use of biguanides, such as metformin, is always associated 
with acidosis and severe gastrointestinal upset [63]. Over the past 30 to 40 years, 
studies using  approaches ranging from epidemiological to interventional and 
molecular technologies have proven that regular exercise is effective in preventing 
and delaying metabolic diseases and its complications [64]. Unfortunately, sustained 
benefits are difficult to achieve due to incapability of human nature to adhere to 
exercise regimen. Also, evolutionarily humans have been driven to minimize energy 
expenditure and remain sedentary. As a result, dietary approach remains a crucial tool 
to achieve the goal of cost-effective management with minimal complications but 
maximal quality of life. Before the introduction of the therapeutic use of insulin, diet 
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is the main form of treatment of the disease, and dietary measures included the use of 
traditional medicines which are mainly derived from plants [65]. Even now, 
approximately 80% of the third-world population is still dependent on traditional 
medicines. Metformin, the most prescribed and first-choice agent in T2DM 
pharmacotherapy, was derived from Galega officinalis (also known as Goat’s rue or 
French lilac), a herb known for relieving symptoms of diabetes since the Middle Ages 
[66].  
In addition, in recent years, a wealth of evidence has been obtained, correlating lower 
consumption of carbohydrate, saturated fat, processed food and higher consumption 
of fruits, vegetables, legumes, coffee, and tea with lower risk of diabetes and 
improved glucose and lipid metabolism. It is evident that plant-based foods are rich in 
phytochemicals known as polyphenols which include flavonoids, phenolic acids, 
lignans and stilbenes, which have been shown to improve glucose homeostasis at 
several organ sites, including the (1) gastrointestinal tract, which regulates 
carbohydrate digestion and glucose absorption, (2) endocrine pancreatic system, 
which secretes key regulatory hormones, insulin and glucagon, in response to 
abnormal glucose levels, (3) liver, where glucose synthesis, glycogen storage and 
breakdown are initiated, (4) insulin-sensitive peripheral tissues like skeletal muscle 
and adipose tissue, where glucose is metabolized for energy or stored for future use. 
1.7 Vernonia amygdalina and diabetes 
Vernonia amygdalina (VA), belonging to the Asteraceae family, is a small shrub that 
is native to South Africa (Figure 1.2). Its medicinal value was first reported in wild 
chimpanzees who suffered from parasite-related disease. They were observed to 
ingest and swallow only the highly bitter juice, spitting out the fibrous remains for 
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self-deparasitization [67, 68]. Since then, investigations were conducted and have 
shown that this plant possesses antimalaria, antihelmintic and antimicobial properties 
[69-72]. Its antioxidant and hepatoprotective activities have also been investigated 
[73-75]. Recently, several reports on anticancer study especially against breast cancer, 
indicate its antineoplastic property [76, 77]. VA is usually known as bitter leaf due to 
its bitter taste. Bitter principles from plants have been associated with the 
improvement in the symptoms of DM [78]. For instance, bitter materials present in 
the decoction from the root of Coccinia indica and from the fruit of Momordica 
charantia were found to be potent to different degrees in some experimental models 
of diabetes [79]. The VA leaves are consumed locally either as vegetables (macerated 
in soup) or aqueous extracts as a tonic for the treatment of various diseases [80]. It is 
well-known for its medicinal importance and is prominently used in Nigeria, Ghana, 
and South Africa for the treatment of diabetes [81, 82]. 
Akah et. al (1992) showed that acute treatment with aqueous  leaf extract of VA 
caused significant reductions of blood glucose levels in both normoglycemic and 
alloxan-diabetic rabbits, comparable to the effect of tolbutamide [83]. The same effect 
was repeated in another study on alloxan-induced diabetic Sprague-Dawley rats. 
Aqueous VA extract (500mg/kg) produced significant reduction in fasting blood 
glucose concentrations of normoglycemic and diabetic rats 1 to 12 hours after acute 
treatment compared to vehicle-treated controls [84]. However, no data on serum or 
pancreatic insulin levels or other parameters was reported in the studies on the acute 
effects of VA. A 28-day study by Nwanjo (2005) [85] of streptozotocin (STZ)-
induced diabetic Wistar rats showed that aqueous VA extract (200mg/kg/twice a day) 
significantly reduced fasting blood glucose levels by more than 50% compared to 
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diabetic controls[85]. Besides, the study provided some data on the hypolipidemic and 
antioxidant activity of VA. Eteng et al. (2008) showed that 400mg/kg of daily 
ethanolic VA extract was able to produce significant hypoglycemic activity in normal 
and alloxan-induced diabetic Wistar albino rats in 21 days, compared to the vehicle-
treated controls [86]. In addition, the improvement in lipid profile is consistent with 
Nwanjo’s findings [85]. Very recently, another chronic study has demonstrated that 
VA significantly reduced fasting glucose levels in both normal and STZ-induced rats 
over a period of 28 days. Histological assessment revealed that protective effect 
against the oxidative effects of STZ was observed in the liver and pancreas treated 
with VA [87]. Ebong et al. (2008) have conducted both acute and chronic studies of 
VA on alloxan-induced diabetic albino Wistar rats. 400 mg/kg of ethanolic VA 
extract caused significant reduction in peak blood glucose levels (47.31%) at 7 hours 
after acute administration, compared to the diabetic controls. In the 24-day chronic 
study, daily administration of 400mg/kg ethanolic VA extract resulted in a significant 
decrease (>80%) in fasting blood glucose levels compared to levels 24 days before 
[88]. Reduction in levels of Glutamic Pyruvic Transaminase (GPT) and Glutamic 
Oxaloacetic Transaminase (GOT), which are markers of hepatotoxicity, are in 
agreement with the hepatoprotective effect of VA [89, 90]. Another interesting study 
showing the glucose-lowering effect of VA was conducted on normal broilers, which 
were treated with VA leaf-meal for 28 days [91].  
On the other hand, Uchenna et al. (2008) conducted a clinical study to investigate the 
effect of VA on blood glucose concentrations of healthy human subjects by using 
“squeeze wash” and “chew raw” methods of administration [92]. Significant 
reductions were shown in levels of fasting and postprandial blood glucose, with 
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improved glucose tolerance, where the peak reduction occurred at 60 minutes post-
administration [92]. An in vitro study provided further evidence for antidiabetic effect 
of VA by showing that it increased glucose utilization in C2C12 muscle cells and 
Chang liver cells [93]. Another in vitro study also showed that VA extracted by 
acetone or ethylacetate possessed inhibitory effect against digestive enzymes, α-
amylase and α-glucosidase [94]. 
From Table 1.1, it is evident that VA possesses hypoglycemic properties in various 
animal models and human studies but the mechanisms of action are yet to be 
elucidated. Furthermore, the active antidiabetic principle(s) from the extract has yet to 
be isolated and identified. 
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1.8 Coffee and diabetes 
The present study has greatly been inspired by the studies of the correlation between 
coffee and diabetes. To date, a total of 13 cohort studies involving 1,247,387 
participants and 9,473 incident cases of T2DM from various populations groups of the 
United States (American [96], African Americans [97]), Europe (England [98], 
Sweden [99]) and Asia (Japan [100], Singapore [101]), have demonstrated an inverse 
correlation between habitual coffee consumption and the development of T2DM. 
However, Battram et al. (2006) showed that the area under the curve (AUC) of 
glucose was significantly lowered during an oral glucose tolerance test (OGTT) 
following consumption of decaffeinated coffee compared with caffeinated coffee and 
a placebo [102]. By using both OGTT [102-105] and euglycemic-hyperinsulinemic 
clamp [105-108] techniques, the acute administration of caffeine had been shown to 
impair insulin sensitivity. Likewise, a 5-day consumption of high doses of caffeine 
induced glucose intolerance [109] while a 7-day consumption of caffeine induced the 
development of insulin resistance [110]. Besides caffeine, coffee contains numerous 
compounds like phenols, diterpenes, trigonelline and minerals such as potassium and 
magnesium. Among them, chlorogenic acid [111-114], trigonelline [111], quinides 
[115] and magnesium [116] have been shown to affect glucose metabolism. As a 
result, attention has been diverted to other components in coffee, in particular the 
major phenolic compound, CGA, which was also found out to be a major constituent 
of VA extract later in our studies. 
1.9 CGA and diabetes 
CGA is a type of hydroxycinnamic acids, which is found in many types of fruits and 
in high concentration in coffee [117]. It is an ester formed from cinnamic acids and 
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quinic acid and is also known as 5-O-caffeoylquinic acid (5-CQA) (IUPAC 
numbering) or 3-CQA (pre-IUPAC numbering) [118]. CGA and its derivatives have 
been shown to inhibit G6P translocase in microsomes of rat livers, suggesting its 
inhibitory role in gluconeogenesis for the first time [119, 120]. It was later found out 
that G6P translocase 1 facilitates the flux of G6P into endoplasmic reticulum in 
enterocytes [121] and a patient genetically deficient in this transporter had been 
shown to experience carbohydrate malabsorption [122]. This reveals the possibility 
that CGA might be able to inhibit and delay intestinal glucose absorption. Another 
study supported this hypothesis by showing that CGA inhibited sodium-dependent 
glucose uptake in rat intestinal brush border membrane vesicles[123].  Besides, at IC50 
of 0.07mM, CGA has also been shown to inhibit porcine pancreatic α-amylase [124]. 
Consistent with this, in an animal study using obese and insulin-resistant Sprague-
Dawley Zucker (fa/fa) rats, CGA was found to lower postprandial hyperglycemia, 
plasma triacylglycerol and cholesterol [125]. Bassoli et al. (2008) also observed a 
significant reduction in plasma glucose peak caused by CGA in an OGTT [114]. In a 
human cross-over trial in obese men, ingestion of 1g CGA caused a significant 
reduction in glucose and insulin levels 15mins after oral glucose load in an OGTT 
[111]. However, no effect was observed on fasting glucose and insulin levels, 
contradicting the previous finding in normaglycemic rats that CGA reduced fasting 
blood glucose level over a period of 5 hours [120]. Karthikesan et al. (2010) showed 
that in STZ-nicotinamide-induced diabetic rats, CGA lowered fasting blood glucose 
levels and restored STZ-diminished insulin levels. Also in the same study, CGA was 
shown to positively modulate several gluconeogenic and glycolytic enzymes, such as 
G6Pase, frutose-1,6-biphosphatase, hexokinase and glucokinase [126]. Svetol, a 
decaffeinated green coffee extract that has a high CGA content, has been shown to 
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inhibit G6Pase in human liver microsomes [127], in line with previous study 
demonstrating that CGA could be a specific inhibitor of G6Pase [112]. Besides, there 
are studies showing that CGA stimulated glucose uptake in L6 myocytes [128] and 
3T3-F442A adipocytes [129], indicating that CGA might be able to regulate fasting 
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1.10 Objectives and Design of Study 
1.10.1 Objectives of study 
Although there are a number of studies investigating the antidiabetic effects of VA, its 
mechanism(s) of action is/are yet unclear. Hence, the present study aims to elucidate 
the possible mechanisms of the hypoglycemic effect of VA, using STZ-induced 
diabetic animal model. Besides, the present study aims to identify active constituents 
in the extract in order to determine possible chemical compounds that may be 
responsible for the hypoglycemic effects. 
On the basis of evidence that (i) VA exerts hypoglycemic effects through inhibition of 
gluconeogenic enzyme activity and increased expression and translocation of GLUT 4 
in skeletal muscle, (ii) VA is rich in CGA and its derivatives, (iii) beneficial 
antidiabetic effects of coffee are not attributable to caffeine, and (iv) CGA possesses 
hypoglycemic effects in human, animal and in vitro models, the present author's next 
aim is to investigate the hypoglycemic effects of CGA in both in vivo and in vitro 
models and to identify its possible mechanism(s) of action. Also, he will examine the 
effect of long-term consumption of CGA as the beneficial metabolic effects of coffee 
on T2DM are associated mainly with the long-term consumption of the beverage. By 
using several pharmacological and molecular inhibitors, he will elucidate whether the 
hypoglycemic effects of CGA are insulin-dependent or non-insulin dependent. Last 
but not least, owing to the fact that T2DM is closely related to obesity and there have 
been a few studies reporting that CGA enhanced fat metabolism in the liver [125, 130], 
he will therefore investigate the effect of CGA on lipid metabolism in both in vivo and 
in vitro models.
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1.10.2 Research design 
Briefly, 6 to 8 week-old male Wistar rats were treated with intraperitoneal STZ 
(65mg/kg) to induce diabetes. After five days, those with fasting blood glucose of 
250mg/dL and above were considered diabetic and selected for the study. They were 
randomly divided into six groups (n=6). The hypoglycemic activity of VA was 
screened using an incremental dose study in an OGTT. The rats were then allowed to 
rest for two weeks to clear away the treatment effects prior to the initiation of the 
long-term (28-day) study. All treatments were given twice daily orally for 28 days. 
Body weight, food and water intakes of the rats were monitored daily. Fasting blood 
glucose was assessed before the initiation of chronic treatment and at the end of the 
study. Serum, pancreas, liver and soleus muscle were collected at the end of the study 
and frozen at -80°C till time of use. 
The author will next use a total T2DM diabetic model, which is the genetically 
modified Lepr
db/db
 mouse for the studies involving CGA. Lepr
db/db
 mouse is a 
spontaneously mutated diabetic model which becomes obese at approximately three to 
four weeks of age. Elevations of plasma insulin begin at 10 to 14 days and elevations 
of blood sugar at four to eight weeks. Homozygous mutant mice are polyphagic, 
polydipsic, and polyuric. The severity of disease with this genetic background leads to 
an uncontrolled rise in blood sugar for which exogenous insulin fails to control blood 
glucose levels. Both metabolic efficiency and gluconeogenic enzyme activities are 
increased in this model (Source: The Jackson Laboratory Database 
http://jaxmice.jax.org/strain/000642.html). 
He will investigate the effect of CGA on glucose tolerance before and after 2-week 
treatment in Lepr
db/db
 mice as the beneficial metabolic effects of coffee on T2DM 
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have been shown to result mainly from the long-term consumption of the beverage. 
He will performe insulin tolerance test to assess effect of CGA on insulin sensitivity. 
He will also examine the effect of 2-week treatment with CGA on various organs 
involved in glucose metabolism, namely the liver and skeletal muscle. HepG2 human 
hepatoma cell line was used to study CGA’s effect on hepatic glucose production.  
The present author will also investigate the effect of CGA on lipid metabolism in both 
in vivo and in vitro models as previous studies [125, 130] have shown that CGA 
enhances fat metabolism in the liver. He will also investigate the effect of CGA on 2-
deoxyglucose (2DG) transport in L6 myotubes. He will subsequently evaluate 
whether these effects of CGA are associated with the activation of AMP-activated 
protein kinase (AMPK) and try to determine the possible upstream target(s) that 








    
2 Chapter 2: Materials and Methods 
2.1 Materials 
CGA, DMEM, Krebs-Ringer bicarbonate buffer (KRBB), antibiotic/antimycotic, 
insulin, wortmannin, cytochalasin B, Fluoroshield with DAPI, Oil Red O, STO-609, 
amyloglucosidase, Light Green SF Yellowish, Pararosaniline hydrochloride and AMP 
were obtained from Sigma (St. Louis, MO, USA). HepG2 hepatocytes were obtained 
from ATCC (Manassas, VA, USA). FBS was from Hyclone (Cramlington, UK). 
DMSO was purchased from MP Biomedicals (Illkirch, France). Hematoxylin and 
Eosin (H&E) stain, glucose oxidase kits, Infinity
TM 
Tryglyceride and Total 
Cholesterol reagent kits were obtained from Thermo Scientific (Waltham, MA, USA). 
Compound c, Orange G stain and NP 40 were obtained from Merck (Darmstadt, 
Germany). [γ-32P]-ATP, NaH14CO and 14C-sodium acetate were purchased from 
PerkinElmer (Waltham, MA, USA). Protease inhibitor cocktail was purchased from 
Abcam (Cambridge, UK). AMPK α1/2 siRNA and an unrelated siRNA (control 
siRNA-A) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 





phospho-AMPK α1/2, anti-AMPK α1/2, anti-ACC, anti-PEPCK, anti-e-cadherin, 
anti-G6Pase and FITC-conjugated rabbit IgG) were also obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Anti-GAPDH and anti-phospho-ACC were 
from Cell Signaling Technology (Danvers, MA, USA) and Millipore (Billerica, MA, 
USA) respectively. Oligofectamine, Alexa Fluor 555-conjugated mouse IgG, Fluo-4 
direct calcium assay kit and OPTI-MEM were purchased from Invitrogen (Carlsbad, 
CA, USA). Bradford protein estimation kit was from Bio-Rad (Hercules, CA, USA). 
Ultra-sensitive Rat Insulin and Leptin ELISA kits were obtained from Crystal Chem 
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Inc. (Downers Grove, IL, USA) while adiponectin ELISA kit was obtained from 
Bertin Pharma (Artigues Pres Bordeaux, France). Free fatty acids detection kits were 
purchased from Wako Diagnostics (Richmond, VA, USA). G-Sepharose beads and 
ECL detection kit were obtained from GE Healthcare (Piscataway, NJ, USA). SAMS 
peptide was purchased from Tocris Bioscience (Minneapolis, MN, USA). 
2.2 Studies of antidiabetic effects of VA in STZ-induced diabetic 
rats 
2.2.1 Plant materials 
Fresh leaves of VA were collected from Penang, Malaysia in January, 2009. Its 
botanical identity, Vernonia amygdalina Delile (Asteraceae) was confirmed by Mr. 
K.F. Leong, a research officer in Singapore Botanic Gardens, National Parks Board. A 
voucher specimen (specimen voucher number: 2007018334) has been deposited in 
SINU Herbarium, National University of Singapore (NUS). 
2.2.2 Preparation of plant extract 
Harvested fresh leaves (3 kg) were rinsed with distilled water and homogenized with 
80% ethanol. The homogenate was extracted over 24 hours at room temperature. The 
extracted mixture was then filtered. The filtrate was concentrated in a rotary 
evaporator at 50°C. Plant residues were again extracted with 80% ethanol for another 
24 hours until exhaustion, followed by filtration and concentration. Accumulated 
filtrate was subjected to freeze drying and the resulting solid residues (62.4 g 
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yellowish green powder) are referred to as “extract” in this paper. The extract yield 
(w/w) from 3 kg of fresh VA leaves was approximately 2.1%. 
2.2.3 Experimental animals 
Sixty male Wistar rats were obtained from Centre for Animal Resources (CARE), 
NUS. They were allowed to acclimatize to conditions in the Animal Holding Unit 
(AHU), NUS, where they were housed throughout the experiment on a 12-hour 
light/dark cycle. Water and feeds were available to the animals ad libitum. The 
Principles of Laboratory Animal Care (NIH, 1985) were followed throughout the 
duration of experiment. The experimental protocol for animal study was approved by 
NUS Institutional Animal Care and Use Committee (IACUC). 
2.2.4 Ethics statement 
The Principles of Laboratory Animal Care (NIH, 1985) were followed throughout the 
duration of the experiment. The experimental protocol for animal study was approved 
by NUS IACUC [Protocol No: 085/07(A3)10]. 
2.2.5 Induction of diabetes with STZ 
Overnight-fasted rats (n=50) were injected with a single intraperitoneal dose of STZ 
(65 mg/kg), which was freshly dissolved in sodium citrate buffer (pH 4.5) [131]. 
Their fasting blood glucose levels were measured five days after the injection, using 
glucose oxidase method. Rats with fasting blood glucose of 250 mg/dL and above 
were considered diabetic and selected for the study. 
2.2.6 Dose-response study in STZ-diabetic rats with VA 
Thirty diabetic rats and six normal rats used in this study were randomly divided into 
six groups (n=6). The anti-hyperglycemic activity of VA was screened by using a 
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modified oral glucose tolerance test. Briefly, blood samples were collected from the 
normal/diabetic rat, followed by oral gavaging of treatments (vehicle, 500 mg/kg 
metformin, 200/400/600 mg/kg VA) for each group of animals. Diabetic rats treated 
with vehicle were assigned as diabetic control (DC) while normal rats treated with 
vehicle were assigned as normal control (NC). Thirty minutes after the treatments, 
blood samples were collected for glucose estimation, followed by oral administration 
of 2 g/kg of glucose. Blood samples were further collected 1 hour and 2 hours post-
glucose loading for glucose estimation. 
2.2.7 Chronic (28-day) study in STZ-diabetic rats 
Two weeks after the dose-response study, the rats were randomly re-grouped for 
chronic treatment. Six rats without STZ treatment were taken as NC and treated with 
vehicle. Eighteen diabetic rats were randomly selected and divided into three groups 
(vehicle, 500 mg/kg metformin and 400 mg/kg VA). All treatments were given twice 
daily orally for 28 days. Body weight, food and water intakes of the rats were 
monitored daily. Fasting blood glucose was assessed before the initiation of chornic 
treatment and at the end of the study. Blood sample, pancreas, liver and soleus muscle 
were collected at the end of the study and frozen at -80°C till the time of use. 
2.2.8 Biochemical analyses 
Pancreatic insulin extraction was done as described previously [132]. Briefly, 0.1 g of 
pancreas tissue was homogenized in 5ml of acetic acid for 1 min by ultrasonic 
disintegration at 4°C. It was left to stand overnight at -20°C. After which it was 
centrifuged at 1000 g for 10 minutes. The supernatant was used for insulin 
measurement. Both serum and pancreatic insulin levels were measured using Ultra-
Sensitive Rat Insulin ELISA kit. Infinity
TM 
Tryglyceride and Total Cholesterol 
30 
    
reagents kits were used for the measurement of serum triglyceride and total 
cholesterol levels. Kits for antioxidant enzyme assays (Superoxide Dismutase, 
Catalase and Glutathione Peroxidase) and glutathione assay were purchased from 
Cayman Chemicals (Ann Arbor, MI, USA). 
2.2.9 Determination of G6Pase activity 
Hepatic G6Pase activity was measured in microsomes isolated from liver as described 
previously [133]. Liver was homogenized in sucrose buffer and centrifuged at 10 000 
g for 10 minutes at 4°C. Supernatant was taken and re-centrifuged at 100 000 g for 45 
minutes at 4°C. The pellets (microsomes) were re-suspended with sucrose buffer for 
assay. The activity of the enzyme was expressed as amount of phosphate liberated 
from G6P in a minute, adjusted to the amount of protein extracted. 
2.2.10 Determination of muscle glycogen content 
Muscle glycogen content was measured according to a protocol described previously 
[134]. Muscle was homogenized in citrate buffer (pH 4.5) and 10 µl of homogenate 
was aliquoted to determine free glucose in the tissue by using glucose oxidase reagent. 
Amyloglucosidase (1mg) was added to 1ml of homogenate and incubated for 4 hours 
at 37°C. Then, 10µl was taken to measure the total glucose content. Glycogen content 
was calculated by subtracting initial free glucose from total glucose and expressed as 
mg/g tissue. 
2.2.11 Fractionation of rat skeletal muscle 
Fractionation of skeletal muscle was done as described previously [135]. The soleus 
muscle was isolated and homogenized in KCl buffer with protease inhibitors at low 
speed. Homogenate was treated with Triton X-100 for 30 minutes at 4°C. It was then 
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centrifuged at 14 000 g for 15 minutes at 4°C. Supernatant was collected as total cell 
lysates and stored for immunoblotting. A solution of KCl was added to the remaining 
homogenate to a final concentration of 0.65 M. The mixture was left on ice for 15 
minutes, followed by centrifugation at 2000 g for 10 minutes at 4°C. Supernatant was 
collected and put on ice. Pellet was re-suspended in KCl buffer and steps were 
repeated. Two supernatants were pooled and centrifuged at 190 000 g for 60 minutes 
at 4°C. Resulting pellet was crude membranes. It was re-suspended in sucrose buffer. 
The re-suspended pellet was then loaded onto the top of a discontinuous sucrose 
gradient (25%, 30% and 35%). The sucrose gradient columns were then subjected to 
ultracentrifugation at 150, 000 g for 16 hours at 4°C. Plasma membrane was collected 
at the top of 25% sucrose while microsomal fraction was collected in between 30-35% 
sucrose. They were re-suspended in KCl buffer and stored for immunoblotting. 
2.2.12 Immunoblotting to detect GLUT 1 and GLUT 4 
Protein extracted was separated with SDS-PAGE and electro-transferred to 
nitrocellulose membranes. Blotted protein was then probed with primary antibodies. 
They were then probed with HRP-conjugated secondary anti-rabbit antibodies. Probed 
proteins were visualized with advanced ECL kit. 
2.2.13 HPLC analysis 
Chemical composition of the extract was analysed using Waters HPLC equipped with 
a photodiode array detector, a Shimadzu ODS-VP column (4.6x250 mm, 5 μm i.d.), 
and an auto-sampler. It was set to scan from 200-400 nm at 25°C. The binary mobile 
phase consists of (A) water-acetic acid (99.9: 0.1, v/v) and (B) CH3CN. The gradient 
elution program was set to 5–13% B (0–4 min), 13–26% B (4–16 min), 26–28% B 
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(16–24 min), 28–36% B (24–32 min), 36–90% B (32–36 min), 90–5% B (36–40 min) 
and 5% B (40–44 min). The injection volume of each sample was 20 µl. The flow rate 
of the mobile phase was set to 1 ml/min and peaks were monitored at 330 nm. 
2.2.14 LC-ESI-MS analysis 
LC-ESI-MS analysis was conducted on Finnigan/MAT LCQ ion trap mass 
spectrometer fitted with an electrospray interface (ESI) and a TSP 4000 HPLC system. 
The LC conditions were identical to those used for HPLC analysis as above. The 
injection volume of each sample was 20 µl. Both positive ion and negative ion modes 
were used for further characterization of the compounds. The heated capillary and 
spray voltage were maintained at 250°C and 4.5 kV, respectively. Nitrogen was 
operated at 80 psi for sheath gas flow rate and 20 psi for auxiliary gas flow rate. Full 
scan mass spectra from m/z 50 to 2000 were recorded with a scan speed of one scan 
per second. MS/MS was operated with the collision energy of 30–40%. Identities of 
the compounds were obtained by matching their molecular ions (m/z) recorded by 
LC-ESI-MS and LC-ESI-MS/MS with existing literature data [136]. 
2.3 Studies of antidiabetic and antilipidemic effects of CGA 
2.3.1 Experimental animals 
Lepr
db/db
 mice homozygous for diabetes spontaneous mutation were obtained from 
The Jackson Laboratory (Sacramento, CA, USA). C57BL/6 mice were purchased 
from CARE, NUS. They were allowed to acclimatize to conditions in the AHU, NUS. 
They were housed throughout the experiment on a 12-hour light/dark cycle. Water 
and feeds were available to the animals ad libitum.  
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2.3.2 Ethic statement 
Refer to Section 2.2.4. 
2.3.3 Oral glucose tolerance test 
Lepr
db/db
 mice were randomly assigned into four groups (n=4) and four C57BL/6 mice 
were assigned as lean control group. They were fasted for six hours before the test. 
For inhibitor study with compound c (AMPK inhibitor), mice were pre-treated with 
50 mg/kg compound c. Blood samples were collected from the tail vein for fasting 
glucose measurement using glucose oxidase method before treatments (vehicle, i.p. 
250 mg/kg CGA, oral 250 mg/kg metformin). Ten minutes after the treatments, blood 
samples were collected again followed by oral gavaging of 2 g/kg glucose. Blood 
samples were collected 15, 30, 60 and 120 minutes after the glucose challenge.  
2.3.4 2-week CGA treatment in Leprdb/db mice 
After the oral glucose tolerance test, the mice were given a one-week rest to clear the 
acute effects of various treatments. They were randomly re-assigned (n=4) and treated 
with vehicle, 250 mg/kg oral metformin or 250 mg/kg CGA i.p. daily. On Day 0, oral 
glucose tolerance test was done followed by initiation of chronic treatment. 
Measurements of body weight, food and water intakes were started and monitored in 
the subsequent days. At the end of the treatment, besides OGTT, insulin tolerance test 
(ITT) and pyruvate tolerance test (PTT) were also performed. For PTT and ITT, 2 
g/kg sodium pyruvate or 0.75U/kg insulin or 3U/kg insulin was injected 
intraperitoneally and blood was sampled as described in OGTT. The mice were then 
sacrificed for collection of whole blood, skeletal muscles (soleus and gastrocnemius) 
and liver. They were frozen immediately in liquid nitrogen and stored at -80ºC till 
time for assays. The score for homeostatic model assessment (HOMAIR) index of 
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insulin resistance was determined from: fasting blood glucose (mg/dL) X fasting 
serum insulin (µU/ml)/ 405 [137]. 
2.3.5 2DG transport in skeletal muscle isolated from Leprdb/db mice 
Skeletal muscles were isolated from Lepr
db/db
 mice as described previously [138]. It 
was then incubated with treatments (vehicle, metformin or CGA) in KRBB for 30 
minutes at 37ºC. Treated muscle strips were subsequently incubated with 0.5 ml 
KRBB containing 1 µCi/ ml 2-Deoxy-[
3
H]D-glucose for 30 minutes at 37ºC. Reaction 
was terminated by immediately blotting the tissues and dissolving them in 0.5N 
NaOH for an hour followed by neutralization with equal amount of 0.5N HCL. After 
centrifugation, supernatant was collected for quatitation of 2DG taken up by the tissue 
using liquid scintillation counter (Beckman Coulter LS6500 Multi-Purpose 
Scintillation Counter, Fullerton, CA, USA). Non-specific uptake was measured in the 
presence of 10 µmol/l cytochalasin B and subtracted from the total uptake. 2DG 
uptake was expressed as a percentage of the basal uptake of cells incubated with 
KRBB buffer only. 
2.3.6 Cell culture and differentiation of L6 skeletal muscle 
The culture was maintained in DMEM containing 10% FBS and 1% 
antibiotic/antimycotic in a humidified atmosphere of 5% CO2 at 37ºC. Differentiation 
of myoblasts into myotubes was carried out as described by Klip et al. [139]. L6 
myoblast was seeded in 10% FBS-DMEM until it reached 80-90% confluence; the 
FBS content was reduced to 2% for a further 5-7 days to induce myotube formation. 
The degree of differentiation was determined as the percentage of nuclei present in the 
multinucleated myotubes under a phase-contrast microscope. Before all experimental 
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manipulations, L6 myotubes were deprived of serum for 4 hours to render the cells 
quiescent. 
2.3.7 Cell culture of HepG2 human hepatoma 
HepG2 human hepatoma was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% FBS under 5% CO2 at 37ºC. Confluent cells were 
serum-starved for four hours before treatment with CGA, metformin and inhibitors at 
indicated concentrations and incubation periods. For inhibitor study, cells were pre-
treated with compound c or STO-609 for 30 minutes before addition of drugs for 
another 4-hour incubation. 
2.3.8 2DG transport in L6 skeletal muscle cells 
The cells were grown and differentiated in 96-well plates as described in section 2.3.6. 
After the indicated periods of incubation with different treatments, the cells were 
rinsed with KRPH (HEPES-buffered Krebs-Ringer phosphate) buffer, consisting of 
118 mmol/l NaCl, 5 mmol/l KCl, 1.3 mmol/l CaCl2, 1.2 mmol/l MgSO4, 1.2 mmol/l 
KH2PO4 and 30 mmol/l HEPES (pH 7.4). CGA was prepared in 5% DMSO and 
diluted with appropriate amount of DMEM to obtain different concentrations. 5% 
DMSO was used for all drug preparations. For the study with CGA + insulin, 
myotubes were treated with 2 mmol/l CGA for 24 hours and stimulated with 100 
nmol/l insulin for 30 mins before 2DG uptake measurement. For the study involving 
inhibitors, myotubes were pre-incubated with 100 nmol/l wortmannin or 10 µmol/l 
compound c for 30 minutes before adding CGA. Washed cells were incubated with 10 
µmol/l 2-Deoxy-[
3
H]D-glucose (1µCi/ml) in KRPH buffer for 30 minutes at 37ºC. 
The 2-DG uptake was terminated immediately by aspirating the radioactive 
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incubation solution and washing three times by ice-cold phosphate-buffered saline 
(PBS). The cells were then lysed with 0.5 N NaOH, followed by 0.5 N HCL for 
neutralization. The quantity of 2DG taken up by the cells was measured with liquid 
scintillation counter. Non-specific uptake was measured in the presence of 10 µmol/l 
cytochalasin B and subtracted from the total uptake. 2-DG uptake was expressed as a 
percentage of the basal uptake of cells incubated with KRPH buffer only. 
2.3.9 Myotube subcellular fractionation 
The subcellular fractionation of myotubes was done as previously described [140]. 
Treated cells were scraped gently from 10 cm dishes and centrifuged at 700 g, 4ºC for 
10 mins. The pellet was then resuspended in sucrose buffer, consisting of 250 mmol/l 
sucrose, 5 mmol/l sodium azide, 2 mmol/l EGTA, 20 mmlol/l HEPES (pH 7.4) and 
protease inhibitor cocktail, and homogenized with 20 strokes using a Dounce 
homogenizer. The homogenate was centrifuged at 760 g, at 4ºC for 5 minutes to 
remove nuclei and cell debris. The supernatant was collected as total cell lysate. For 
plasma membrane isolation, the supernatant was removed and centrifuged at 31,000 g, 
4ºC for 60 minutes to pellet the crude plasma membrane (PM). PM fraction was 
resuspended in sucrose buffer and stored at -80ºC.  
2.3.10 siRNA transfection of myotubes and HepG2 
Transfection of siRNA into myotubes was done as described previously with a minute 
modification [141]. Cells were seeded and grown in 6-well plates as described earlier 
(see section on cell culture and differentiation). After cells were treated with 2% FBS 
for 3 days, siRNAs were transfected with oligofectamine, according to the instructions 
of the manufacturer. Briefly, the complex mixture in serum- and antibiotic-free OPTI-
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MEM was layered onto the cells and incubated for 4 hours at 37ºC. The serum content 
was then brought up to 2% by adding half volume of antibiotic-free DMEM 
supplemented with 6% FBS and incubated for an additional 20 hours. Another volume 
of 2%-FBS DMEM with antibiotic was then added and incubated for further 24 hours 
to allow the siRNA to remain on the cells for a total of 48 hours. For HepG2 cells, 
Confluent cells were transfected with siRNAs in oligofectamine according to the 
instructions of the manufacturer. Briefly, the complex mixture in serum- and 
antibiotic-free OPTI-MEM was layered onto the cells and incubated for 8 hours at 
37ºC. The medium was then replaced with DMEM containing 10% FBS and 
incubated for an additional 48 hours. Efficiency of transfection was optimized using 
FITC-tagged siRNA. 
2.3.11 Immunoprecipitation and detection of association between IRS-1 and p85 
subunit of PI3K 
Treated cells were scraped gently from 6-well plate and pelleted with ice-cold PBS at 
3,000 rpm, 4ºC for 5 minutes. Cell pellet was then lysed in lysis buffer (50 mmol/l 
Tris [pH 8], 170 mmol/l NaCl, 1 mmol/l DTT, 0.5% NP40  and protease inhibitor 
cocktail for 30 minutes at 4ºC. Cell lysate was then centrifuged at 13,000 rpm for 10 
minutes to remove cell debris. Cell lysate (2 µl) was used for Bradford protein 
estimation. Total cellular protein (1 mg) was immunoprecipitated with 1 µg of anti-
IRS-1 antibody coupled to 40 µl of 100 mg/ml protein G-Sepharose beads. 
Immunoprecipitated proteins, together with the beads, were separated with SDS-
PAGE and blotted as mentioned in the western blot analysis below. Blotted proteins 
were probed with anti-PI3K p85α antibody. 
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2.3.12 Glucose production assay 
Treated cells were washed with PBS. Glucose-free glucose production buffer (phenol 
red-free DMEM supplemented with 2 mmol/l sodium pyruvate, 20 mmol/l sodium 
lactate and 44 mmol/l sodium bicarbonate) was added and incubated for four hours. 
After that, medium was collected for the measurement of glucose, using the glucose 
oxidase kit. The readings were then normalized to the total protein content. 
2.3.13 AMPK activity assay 
AMPK activity was measured as described previously [142]. HepG2 cells were 
treated with CGA at different concentrations for indicated periods of time. Treated 
cells were scraped and pelleted with ice-cold PBS at 3,000 rpm, 4ºC for 5 minutes. 
Cell pellets were then lysed in lysis buffer containing 150 mmol/l NaCl, 50mmol/l 
Tris (pH 8.0), 10 mmol/l sodium fluoride, 1 mmol/l sodium pyrophosphate, 1 mmol/l 
sodium orthovanadate, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate and protease inhibitor cocktail. 2 µl of the cell lysate was used for Bradford 
protein estimation. 1 mg of total cellular protein was immunoprecipitated with 1 µg of 
anti-AMPK α1/2 antibody coupled to 40 µl of 100 mg/ml protein G-Sepharose beads. 
Kinase reaction was carried out on washed immunoprecipitate in 40 mmol/l HEPES 
(pH 7.0), 0.2 mmol/l AMP, 80 mmol/l NaCl, 0.8 mmol/l DTT, 5mmol/l MgCl2, 0.2 
mmol/l ATP (2mCi [γ-ATP]) and 0.1 mmol/l SAMS peptide for 20 minutes at 37ºC. 
Reaction mixture was then spotted on P81 Whatman filter paper and washed 
extensively using phosphoric acid and acetone. Radioactivity on the filter paper was 
measured by liquid scintillation. Kinase activity was expressed as incorporated 
ATP/mg protein/minute. 
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2.3.14 ACC activity assay 




 into malonyl 
CoA [143]. Treated HepG2 cells were lysed in lysis buffer containing 150 mmol/l 
NaCl, 50mmol/l Tris (pH 8.0), 10 mmol/l sodium fluoride, 1 mmol/l sodium 
pyrophosphate, 1 mmol/l sodium orthovanadate, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate and proteases inhibitors cocktail. Cell 
lysate (2 µl) was used for Bradford protein estimation. ACC activity was measured by 
incubating lysates with reaction mixture consisting of 50 mmol/l HEPES (pH7.5), 10 
mmol/l potassium citrate, 10 mmol/l MgCl2, 4 mmol/l potassium carbonate, 0.5 
mmol/l adenosine triphosphate, 0.4 mmol/l NaH
14
CO3, 0.25 mmol/l acetyl CoA and 
0.075% bovine serum albumin for 40 minutes at room temperature. The reaction was 
stopped by adding in half volume of 1N HCL and allowing to stand for 30 minutes at 
room temperature. Total 
14
C incorporated was measured using a liquid scintillation 
counter (Beckman Coulter LS6500 Multi-Purpose Scintillation Counter, Fullerton, 
CA, USA). ACC activity was expressed as incorporated 
14
C /mg protein/minute. 
2.3.15 Fatty acid synthesis assay 
Fatty acid synthesis was assayed as described previously with slight modification 
[143]. After the appropriated treatment, medium was removed and replaced with 
serum-free DMEM containing 
14
C-sodium acetate (2µCi/ml). Cells were then 
incubated with the radiolabelled acetate for 4 hours at 37ºC. Radioactive medium was 
then removed and washed immediately with ice-cold PBS for three times. 0.5N NaOH 
was added to lyse the cells followed by neutralization with equal volume of 0.5N 
HCL. Radioactivity incorporated into fatty acid was monitored using scintillation 
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counter. Readings were expressed as percent inhibition of fatty acid synthesis 
compared to control. 
2.3.16 Fluo-4 direct calcium assay 
Measurement of free Ca
2+ 
influx was performed on HepG2 hepatoma cells according 
to the instructions of the manufacturer. Briefly, treated cells were incubated with 
equal volume of 2X Fluo-4 Direct calcium reagent for one hour at 37˚C. Fluorescence 
was measured at 494 nm (excitation) and 516 nm (emission) with a microplate reader 
(Tecan Infinite m200, Mannedorf, Switzerland).  
2.3.17 Oil Red O staining 
Treated cells were washed with ice-cold PBS. The cells were then fixed with 10%-
buffered formalin for 24 hours at room temperature. Fixed cells were stained with Oil 
Red O in 60% isopropanol for ten minutes at room temperature. Stained cells were 
washed with deionized water and images were acquired for analysis. Quantitation was 
done by eluting the stain with 100% isopropanol. OD was measured at 500nm. 
2.3.18 Glucose and lipid profiles 
Following manufacturers’ protocols, different enzymatic or ELISA kits were used for 
the measurement of serum glucose, insulin, triglyceride, total cholesterol, adiponectin 
and free fatty acid levels. For hepatic lipids measurement, tissue was homogenized in 
10% w/v isopropanol and kept at 4ºC for two days. Homogenate was centrifuged at 
4ºC and 1000g for 10 minutes. Supernatant was collected for the measurements of 
triglyceride, cholesterol and free fatty acids. 
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2.3.19 Hepatic G6Pase activity 
Refer to Section 2.2.9. 
2.3.20 Fractionation of skeletal muscle 
Skeletal muscles (soleus and gastrocnemius) isolated from Lepr
db/db
 mice after 2 
weeks of treatments. Please refer to Section 2.2.12 for details in skeletal muscle 
fractionation. 
2.3.21 2DG transport in skeletal muscles 
Refer to Section 2.3.5. 
2.3.22 Liver histology or skeletal muscle immunohistochemistry 
Isolated skeletal muscle and liver samples were fixed in 10% buffered formalin for 24 
hours at 4ºC. Fixed tissues were then processed using standard tissue processing 
protocol. Processed tissues were embedded in paraffin and sectioned into 4µm-thick 
slices. Tissue sections were dewaxed and hydrated in descending concentrations of 
ethanol. Liver sections were stained with H&E for normal histological assessment, 
where cytoplasm stained pink, nuclei stained deep purple and pancreatic islets 
appeared pale in color. Antigen retrieval was then performed on skeletal muscle by 
boiling tissue sections in Tris-EDTA buffer containing 10 mmol/l Tris (pH 9), 1 
mmol/l EDTA and 0.05% Tween 20 for 20 minutes. The tissuee were then blocked 
with 1% bovine serum albumin in TBS supplemented with 0.1% Tween 20. After that 
tissues were incubated in a mixture of primary antibodies (anti-GLUT 4 and anti-e-
cadherin) overnight at 4ºC. Tissue sections were washed and incubated in a mixture of 
FITC-conjugated rabbit IgG and Alexa Fluor 555-conjugated mouse IgG secondary 
antibodies. They were then mounted with Fluroshield with DAPI. 
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2.3.23 Western blot analysis 
Treated HepG2 cells were scraped from 6-well plates and pelleted with ice-cold PBS 
at 3,000 rpm, 4ºC for 5 minutes. Cell pellets were then lysed in lysis buffer containing 
150 mmol/l NaCl, 50mmol/l Tris (pH 8.0), 10 mmol/l sodium fluoride, 1 mmol/l 
sodium pyrophosphate, 1 mmol/l sodium orthovanadate, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate and protease inhibitor cocktail. To 
extract protein from liver, liver tissue was first homogenized in lysis buffer. The 
lysate was then centrifuged at 14,000rpm for 10 minutes. Supernatant was collected 
and separated via SDS-PAGE and the separated proteins were then blotted onto 
nitrocellulose membrane. Membranes were probed with anti-GAPDH, anti-e-cadherin, 
anti-GLUT 4, anti-PEPCK, anti-G6Pase, anti-CAMKKβ, anti-phospho-AMPK α1/2, 
and anti-phospho-ACC. They were then developed using the ECL detection kit. 
2.4 Statistical analysis 
Experiments were repeated three times, each time in triplicate. Values are expressed 
as mean ± SE. One-way ANOVA followed by Tukey’s t test was used to determine 




    
3 Results 
3.1 Studies of antidiabetic effects of VA in STZ-induced diabetic 
rats 
3.1.1 Acute effect of VA extract on fasting blood glucose in STZ-induced 
diabetic rats 
Figure 3.1.1 shows the acute hypoglycemic effect of various treatments on blood 
glucose level measured at various time intervals. The values are percent change in 
blood glucose level at time t, relative to blood glucose level at time -0.5 hour (% 
Change = At/ A-0.5 X 100). Thirty minutes after various treatments at time -0.5 hour, 
metformin caused 4.4% decrease of blood glucose whereas 400 mg/kg of VA, which 
was found to be the most potent dose, resulted in a slight increase of 1.3%. After 
glucose loading at time 0 hour, a surge of 36.6% was observed in DC compared to 
15.2% in NC at time 1 hour, which indicates an impaired glucose tolerance in DC. 
Metformin and VA continued to cause a 54.5% and 25.4% suppression on glucose 
elevation for the first hour after glucose loading if compared to DC, respectively, 
indicating an improvement of glucose tolerance. For the second hour post-glucose 
loading, metformin-treated group showed 74.3% suppression in blood glucose while 
VA showed a 35.2% suppression on increased blood glucose. Metformin suppressed 
the rise in glucose levels, with glucose levels significantly lower than those of NC; on 





    
Figure 3.1.1 Acute effects of VA on glucose tolerance in STZ-induced diabetic rats  
 
 
Treatments were given at time -0.5 hour and glucose was loaded at 0 hour. Blood 
samples were collected at -0.5 hour, 0 hour, 1 hour and 2 hour for blood glucose 
assessment.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic. * P<0.05. 
 
3.1.2 Long-term effects of VA extract on body weight, food and water intakes 
of STZ-induced diabetic rats 
Table 3.1.1 shows the effects of various treatments on body weight, food and water 
intakes of the rats. After 28 days of treatment, both metformin and VA (400mg/kg) 
showed significant decreases in body weight compared to DC. However, there was no 
significant difference in food intake for all the experimental groups. On the other hand, 
there were significant reductions in water intake for metformin- and VA-treated 
groups, compared to DC. 
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Table 3.1.1.  Long-term effect s of VA on body weight, food intake and water 
intake in STZ-induced diabetic rat. 
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 Values were expressed as mean ± S.E.M. (n=6); *P<0.05 compared to DC. 
 
3.1.3 Long-term effects of VA extract on fasting blood glucose, triglyceride and 
total cholesterol levels 
One week after STZ injection, an increase of 140% in fasting blood glucose was 
observed compared to NC. After 28-day treatments, fasting blood glucose of DC 
group continued to rise for another 9% while significant decreases of 36.1% and 
26.5% were observed in metformin-treated and VA-treated groups respectively. 
Compared to DC, there were decreases of 35.3% and 32.1% respectively in fasting 
blood glucose of metformin- and VA-treated groups (Figure 3.1.2). Triglyceride level 
of DC was observed to be 140% higher than NC. There was a significant 18.2% 
reduction in VA-treated group compared to vehicle in DC while no significant change 
was observed in metformin-treated group (Figure 3.1.3A). Total cholesterol level was 
increased in DC by 120% compared to NC. However, VA treatment lowered total 
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cholesterol level by 41%, compared to vehicle in DC. Metformin showed no 
significant effect on total cholesterol level (Figure 3.1.3B). 
Figure 3.1.2.  Long-term effects of VA on fasting blood glucose of STZ-induced 
diabetic rats.  
 
Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavage for 28 days. Blood samples were collected at 
the end of first and last week for glucose level determination.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 







    
Figure 3.1.3. Long-term effects of VA on lipid profile of STZ-induced diabetic rats  
  
Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavage for 28 days. Blood samples were collected at 
the end of day 28 for the determination of A: triglyceride and B: total cholesterol.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic.  * P<0.05 compared to DC. 
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3.1.4 Long-term effects of VA extract on pancreatic and serum insulin levels 
STZ depleted pancreatic and serum insulin levels by up to 95%, compared to NC. 
After the treatments for 28 days, there were significant increases of 54% and 58% in 
pancreatic and serum insulin levels respectively, caused by VA administration, 
compared to vehicle in DC. However, there was no significant change caused by 
metformin in both pancreatic and serum insulin levels (Figure 3.1.4A & B). 
Nonetheless, pancreatic and serum insulin levels from all the diabetic rats are 
negligible if compared to NC.  
3.1.5 Long-term effects of VA extract on hepatic G6Pase activity 
STZ caused an increase of hepatic G6Pase activity compared to NC. Metformin, a 
gluconeogenesis suppressor, restored the G6Pase activity to near-normal, by an 
approximate reduction of 76% compared to DC. On the other hand, 400 mg/kg VA 
was found to decrease G6Pase activity by 40% compared to vehicle in DC (Figure 
3.1.5). 
3.1.6 Long-term effects of VA extract on hepatic GSH and antioxidant enzymes 
STZ-induced diabetic rats were observed to have decreased hepatic GSH levels and 
antioxidant enzyme activities (SOD, catalase, and GPx) compared to NC (Figures 
3.1.6). Metformin treatment did not produce significant changes in both hepatic GSH 
and antioxidant enzymes. VA significantly increased SOD (Figure 3.1.6A) and 
catalase activities (Figure 3.1.6B) by 129% and 39.2% respectively compared to 
vehicle in DC. VA enhanced GPx activity significantly compared to vehicles in both 
DC and NC (Figure 3.1.6C).  In addition, VA restored the glutathione level to near-
normal (Figure 3.1.6D). 
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Figure 3.1.4. Long-term effects of VA on insulin levels of STZ-induced diabetic rats 
 
 
Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days.  
A: Pancreas was isolated at the end of day 28 for the determination of pancreatic 
insulin level. B: Blood samples were collected at the end of day 28 for the 
determination of serum insulin level. Values were expressed as mean ± S.E.M. (n=6). 
NC=Normal Control, DC=Diabetic Control, Metformin=metformin-treated diabetic, 
VA=Vernonia amygdalina-treated diabetic.  * P<0.05 compared to DC. 
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Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days.  
Liver was isolated at the end of day 28 for the determination of G6P level. Values 
were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic Control, 
Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated diabetic.   







    
Figure 3.16. Long-term effects of VA on hepatic antioxidant enzymes and GSH 
activities of STZ-induced diabetic rats 
 
 
Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Liver was isolated at the end of 
day 28 for the determination of A: SOD and B: catalase activities.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic.  * P<0.05 compared to DC. 
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Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Liver was isolated at the end of 
day 28 for the determination of C: GPx activity and D: glutathione level.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 





    
3.1.7 Long-term effects of VA extract on expression of GLUT 1/ GLUT 4 and 
cellular distribution of GLUT 4 
There was a decrease in total expression of GLUT 4 (~40%) but no change in total 
expression of GLUT 1 in DC, compared to NC. Metformin almost restored GLUT 4 
expression to the normal state while VA caused a significant increase of GLUT 4 
expression by 24% compared to vehicle in DC. Neither metformin nor VA affected 
the expression of GLUT 1 (Figure 3.1.7A). Translocation of GLUT 4 to plasma 
membrane was reduced by 75% after treatment with STZ. Chronic administration of 
metformin or VA significantly increased translocation of GLUT 4 to the plasma 




-ATPase was used as plasma membrane 





ATPase in different treatment groups (Figure 3.1.7b). A higher portion of GLUT 4 
was observed to be retained in the light microsomal pool in DC compared to NC. 
Metformin and VA treatments decreased the light microsomal GLUT 4 pools by 














    
Figure 3.1.7.  Long-term effects of VA on skeletal muscle GLUT 4 expression and 

















































Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Soleus muscle was isolated for 
the determination of A: total GLUT 4 expression through SDS-PAGE and 
immunoblotting. Images shown are representative of the corresponding treatment 
group.   
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 




    
B











































Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Soleus muscle was isolated for 





-ATPase was used as a plasma membrane marker. 
Images shown are representative of the corresponding treatment group.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic.  * P<0.05,  **
  




























































































Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Soleus muscle was isolated for 
the determination of C: amount of GLUT 4 remains on intracellular membranes 




-ATPase was used as a plasma 
membrane marker. D: Ratio of plasma membrane/inner membranes GLUT4. Images 
shown are representative of the corresponding treatment group.   
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic.  * P<0.05,  **
  




    
3.1.8 Long-term effects of VA extract on muscle glycogen synthesis 
STZ caused a decrease of 77% in muscle glycogen content compared to NC (Figure 
3.1.8). Metformin significantly increased the glycogen level, compared to both DC 
and NC, whereas VA only restored the glycogen level to normal. 
Figure 3.1.8.  Long-term effects of VA on skeletal muscle glycogen levels in STZ-
induced diabetic rats.  
 
 
Treatments (500mg/kg metformin, 400mg/kg VA and vehicles for both NC and DC) 
were given twice daily through gavaging for 28 days. Soleus muscle was isolated for 
the determination of glycogen level.  
Values were expressed as mean ± S.E.M. (n=6). NC=Normal Control, DC=Diabetic 
Control, Metformin=metformin-treated diabetic, VA=Vernonia amygdalina-treated 
diabetic. 
 




    
3.1.9 Determination of main active constituents in VA extract 
Figure 3.1.9 shows HPLC profile of ethanolic VA extract at 330 nm. 4 main peaks 
were observed and further characterized by LC-ESI-MS analysis. Comparison 
between previous literature data and LC-ESI-MS profile (peak # refers to those in 
Figure 3.1.9) [Table 3.1.2] suggested that the 4 main components are 1,5-dicaffeoyl-
quinic acid, dicaffeoyl-quinic acid, chlorogenic acid and luteolin 7-O-glucoside. 
 














HPLC analysis was performed at a mobile phase flow rate of 1mL/min, and the peaks 





    
Table 3.1.2.  Chemical profile of ethanolic extract of VA. 
 
3.2 Studies of antidiabetic and antilipidemic effects of CGA 
3.2.1 CGA lowers blood glucose levels in an OGTT on Leprdb/db mice 
Compared to lean control, glucose levels of DC group are significantly higher at all 
time points during the OGTT, with a significant 127.7% higher in the total AUC. As a 
positive control, metformin reduced fasting glucose levels in a near-linear manner 
especially after glucose loading, with a suppression of 48.8% total AUC, compared to 
DC. Intraperitoneal 250 mg/kg CGA decreased fasting blood glucose levels of 
Lepr
db/db
 mice by 29.8±5% in the first 10 minutes before glucose challenge. After 
glucose loading, the glucose-lowering effect continued to increase up to 35.7±4% for 
30 minutes. At 2 hours post-glucose loading, this effect diminished gradually and the 
fasting glucose levels returned to that observed in -10-minute (Figure 3.2.1). The 
AUC of CGA-mediated glucose lowering decreased by 49.6%, compared to DC 
(Figure 3.2.1B). However, this hypoglycemic effect of CGA was abated by pre-
intraperitoneal administration of compound c, an AMPK inhibitor (Figure 3.2.1A). 
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compound c was still lower compared to DC (Figure 3.2.1B). Interestingly, we 
observed a decrease in the efficiency of compound c in inhibiting the glucose-
lowering effect of CGA after 15-day treatment with CGA. Instead, a higher dose of 
compound c (100mg/kg) was required to achieve similar inhibitory effect on the 
OGTT curve (Figure 3.2.2A). Figure 3.2.2B shows AUC of OGTT after 
administration of compound c at Day 0 and Day 15. Efficiency of compound c 
(50mg/kg) in inhibiting glucose-lowering effect of CGA was decreased by 21.5% 














    
Figure 3.2.1.  Acute effects of CGA on glucose tolerance in Lepr
db/db
 mice and effect 
of compound c on CGA-mediated glucose lowering 
 
A: Oral glucose tolerance test was performed in 6-hour fasted Lepr
db/db
 mice. For the 
inhibitor study, mice were pre-treated with compound c for 10 minutes. Blood 
samples were collected from the tail vein for fasting glucose measurement before 
treatments (vehicle, i.p. 250 mg/kg CGA, oral 250 mg/kg metformin). Ten minutes 
after the treatments, blood samples were collected again followed by oral gavaging of 
2 g/kg glucose. Blood samples were collected 15, 30, 60 and 120 minutes after the 
glucose challenge. B: AUC of fasting glucose levels in OGTT (A).  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 
*P<0.05 compared to CGA only-treated mice, #P<0.05 compared to lean control. 
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Figure 3.2.2. Decreased inhibitory effect of compound c in suppressing CGA-
mediated glucose lowering after 2-week treatment with CGA 
 
A: Efficiency of different concentrations of compound c in inhibiting CGA-mediated 
glucose lowering was measured before and after 2-week treatment with CGA. Pre-
treatment of compound c was performed intreaperitoneally 10 mins before 
administration of CGA. B: AUC of fasting glucose levels in OGTT (C).  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to mice treated with 
compound c at Day 0. 
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3.2.2 2-week treatment with CGA reduces body weight, water intake and 
improves glucose and lipid profiles 
Lepr
db/db
 mice demonstrated apparent phenotypes of metabolic syndromes including 
glucose intolerance, hyperinsulinemia, obesity, polyphagia, polydipsia and 
dyslipidemia as compared to lean C57BL/6 mice (Table 3.2.1 and Figure 3.2.3A-F).  
Lepr
db/db
 mice showed significantly higher food and water intakes, body weight, 
fasting glucose and insulin levels, serum triglyceride (TG), total cholesterol (TC), and 
free fatty acids (FFA). However, serum adiponectin was significantly lower in 
Lepr
db/db
 mice, compared to lean animals. Lepr
db/db
 mice treated with CGA or 
metformin showed similar food intakes which were significantly lower compared to 
vehicle-treated DC. Together with improved lipid profiles (reduced serum TG, TC 
and FFA) (Figure 3.2.3C-E), CGA- or metformin-treated animals demonstrated a 
significant reduction in body weights. A day after treatments with CGA or metformin, 
water intakes of the animals were found to be significantly decreased, indicating 
improved blood glucose level which will otherwise cause excessive urination and 
thirst, owing to the excretion of excessive glucose in urine (glucosuria). This 
condition continued to improve over the 2-week treatment with CGA or metformin 
(Table 3.2.1). Consistent with this, fasting glucose (Figure 3.2.3A) and insulin (Figure 
3.2.3B) levels in the CGA- or metformin-treated groups were significantly lower 





    





Serum was collected after the chronic treatment for the measurement of A: fasting 
glucose and B: fasting insulin levels.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 




    
 
 
Serum was collected after the chronic treatment for the measurement of C: total 
cholesterol and D: triglyceride levels.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 




    
 
 
Serum was collected after the chronic treatment for the measurement of E: free fatty 
acids and F: adiponectin levels.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 
#P<0.05 compared to lean control. 
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G: At the end of the study, ITT was performed on the animals. Blood samples were 
collected from tail vein for fasting glucose measurement 15, 30, 60 and 120 minutes 
after insulin injection. H: AUC of fasting glucose levels in ITT (G).  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control 




    
 
 
I: HOMAIR index of insulin resistance was determined as: fasting blood glucose 
(mg/dL) X fasting serum insulin (µU/ml)/ 405.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 













    
Table 3.2.1.  Body weights, food and water intakes in Lepr
db/db
 mice following 2-
week treatment with CGA or metformin 
Treatment Body Weight (g) Food Intake (g/kg) Water Intake (g/kg) 
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 








DC 51.5 ± 4.4 
# 















































*P<0.05 compared to DC, #P<0.05 compared to lean control 
 




Insulin resistance is a major concomitant phenotype associated with obesity in 
Lepr
db/db
 mice. Compared to lean control, they showed an approximate five-fold 
incease in HOMAIR index. However, CGA or metformin treatment significantly 
attenuated insulin resistance by 60% and 53% respectively in this diabetic model 
(Figure 3.2.3I), consistent with increased insulin sensitivity in an ITT after 2-week 
treatment with CGA (Figure 3.23G-H).  In the ITT, exogenous insulin (0.75U/kg) did 
not cause significant lowering of glucose levels in DC, compared to NC. The effect 
can only be seen by injecting 4X the normal concentration of insulin (3U/kg). 
However, after 2-week treatment with CGA, 0.75 U/kg insulin significantly decreased 
blood glucose levels, comparable to those achieved by 3 U/kg insulin in DC, 
indicating attenuated insulin resistance. This was further supported by the insulin area 
under the curve (AUCinsulin) in an OGTT. AUCinsulin  was higher in Lepr
db/db
 mice 
compared to lean C57BL/6 and it was significantly elevated after two weeks, 
suggesting diminished insulin sensitivity (3.2.4B&D). Treatment with CGA or 
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metformin for 15 days significantly lowered AUCinsulin in the OGTT, suggesting 
improved insulin sensitivity (Figure 3.2.4B&D). In addition, glucose area under curve 
(AUCglucose) was also significantlyly reduced after 15-day treatment with CGA or 
metformin, compared to DC (Figure 3.2.4A&C). This indicates that both CGA and 
















    
Figure 3.2.4. Chronic effects of CGA on glucose tolerance and insulin levels in 
Lepr
db/db




A: Oral glucose tolerance test was performed in 6-hour fasted Lepr
db/db
 mice. Blood 
samples were collected from the tail vein for glucose levels measurement before 
treatments (vehicle, i.p. 250 mg/kg CGA, oral 250 mg/kg metformin). Ten minutes 
after the treatments, blood samples were collected again followed by oral gavaging of 
2 g/kg glucose. Blood samples were collected 15, 30, 60 and 120 minutes after 
glucose challenge for the measurement of glucose levels. Results were compared to 
those obtained from the acute study at Day 0.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05, **P<0.01 compared to respective 




    
 
 
B: Oral glucose tolerance test was performed in 6-hour fasted Lepr
db/db
 mice. Blood 
samples were collected from the tail vein for insulin levels measurement before 
treatments (vehicle, i.p. 250 mg/kg CGA, oral 250 mg/kg metformin). Ten minutes 
after the treatments, blood samples were collected again followed by oral gavaging of 
2 g/kg glucose. Blood samples were collected 15, 30, 60 and 120 minutes after the 
glucose challenge for the measurement of insulin levels. Results were compared to 
those obtained from the acute study at Day 0.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05, **P<0.01 compared to respective 






    
 
 
C: AUC of fasting glucose levels in OGTT (A). D: AUC of fasting insulin levels in 
OGTT (B). Results were compared to those obtained from the acute study at Day 0.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05, **P<0.01 compared to respective 





    
3.2.4 CGA inhibits gluconeogenesis in Leprdb/db mice through downregulation of 
gluconeogenic G6Pase 
To assess the effect of CGA on gluconeogenesis in vivo, the present author performed 
a pyruvate tolerance test (PTT), as administration of the gluconeogenic substrate 
(pyruvate) increases blood glucose level by promoting gluconeogenesis in the liver. 
Pyruvate intolerance indicated hepatic insulin resistance in DC (>100% increase in 
AUC of pyruvate tolerance test, compared to normal lean control) [Figure 3.2.5A-B]. 
Treatment with CGA or metformin significantly ameliorated pyruvate intolerance 
(28% and 35% reduction in AUC, respectively, compared to Lepr
db/db
 mice). Also, 
elevation of glucose levels induced by sodium pyruvate was effectively lowered by 
CGA at all time points of the test. To further investigate the effect of CGA on hepatic 
insulin resistance in Lepr
db/db 
mice, he examined its effect on hepatic gluconeogenic 
enzymes, G6Pase and PEPCK. As expected, under the condition of the hepatic insulin 
resistance, the expressions of G6Pase and PEPCK were significantly increased in 
Lepr
db/db 
mice (Figure 3.2.6A). Both CGA and metformin decreased the expression of 
G6Pase but they did not affect the expression of PEPCK. Consistent with this, the 










    
Figure 3.2.5. CGA decreases glucose production from gluconeogenic pyruvate in a 




A: Pyruvate tolerance test was performed on 6-hour fasted Lepr
db/db
 mice. Mice were 
treated with vehicle, ip 250 mg/kg CGA, oral 250 mg/kg metformin. Ten minutes 
after the treatment, blood samples were collected for the measurement of blood 
glucose levels, followed by ip administration of 2 g/kg sodium pyruvate. Blood 
samples were collected 15, 30, 60 and 120 minutes after the pyruvate challenge. B: 
AUC fasting glucose levels in PTT (A).  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. #P<0.05 compared to lean control, *P<0.05 
compared to diabetic control. 
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After 2-week treatment, liver was collected and homogenized for A: Quantitation of 
gluconeogenic genes expression, using immunoblotting. 
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 






    
 
 
After 2-week treatment, liver was collected and homogenized for B: microsomes 
isolation and measurement of G6Pase activity.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 











    
3.2.5 Suppression of glucose production and G6Pase expression in HepG2 
hepatoma by CGA 
To further evaluate the role of CGA on gluconeogenesis, the present author studied 
the effect of CGA on glucose production in HepG2 hepatoma cells. As shown in 
figure 3.2.7A & B, CGA effectively inhibited glucose synthesis in vitro, in dose- and 
time- dependent manners, for up to 50%, as compared to vehicle. In addition, 
expression of G6Pase in HepG2 was correspondingly inhibited by CGA, suggesting 
an evident role of CGA on gluconeogenesis inhibition through the regulation of 
G6Pase (Figure 3.2.7C & D). Again, he did not detect any changes in the expression 
of PEPCK by CGA or metformin in HepG2 cell line.  
3.2.6 CGA ameliorates hepatic lipid accumulation, triglyceride and total 
cholesterol levels in Lepr
db/db
 mice 
Non-alcoholic fatty liver or non-alcoholic hepatic steatosis is one of the metabolic 
syndromes caused by impaired leptin signaling [144]. Due to the disruption of leptin 
signaling in this animal model, histological examination of the liver in Lepr
db/db
 mice 
showed lipid accumulation in the vesicles of hepatocytes and eventually fatty 
degeneration of hepatocytes (arrows) [Figure 3.2.8]. Treatment with CGA or 
metformin significantlyly attenuated the vacuolar degeneration, as shown by the 
significant decrease in the formation of fat vacuoles in the liver sections. Likewise, 
triglyceride and total cholesterol levels in the liver of Lepr
db/db
 mice were higher 
(more than 2 times), if compared to lean control. Treatment with metformin or CGA 
significantly improved the elevated lipids content in the liver (Figure 3.2.9 A-B). 
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Figure 3.2.7. CGA suppresses glucose production and expression of G6Pase in 
HepG2 hepatoma cells. 
 
 
HepG2 hepatoma cells treated in various A: doses of CGA and B: incubation periods  
were washed and incubated with glucose production buffer for four hours. Medium 
was collected for the measurement of glucose produced. Readings were then 
normalized to the total protein content.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 
**P<0.01 compared to vehicle-treated control. 
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C: HepG2 cells treated in various doses of CGA were lysed for the quantitation of 
gluconeogenic genes expression, using immunoblotting.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 







    
 
 
D: HepG2 cells treated in various incubation periods were lysed for the quantitation of 
gluconeogenic genes expression, using immunoblotting.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 






    







Isolated livers were fixed in 10% buffered formalin for 24 hours at 4ºC. Fixed tissues 
were processed and sectioned into 4µm-thick slices. Tissue sections were stained with 
H&E for normal histological assessment, where cytoplasm stained pink and nuclei 
stained deep purple.  
Arrows indicate vacuoles formed as a result of lipid accumulation. Images shown 
(scale bar = 50 µm) are representatives of the corresponding treatment group. 





    
Figure 3.2.9. CGA lowers hepatic triglyceride and total cholesterol levels. 
 
 
Liver was homogenized in 10% w/v isopropanol and kept at 4ºC for two days. 
Homogenate was centrifuged at 4ºC and 1 000g for 10 minutes. Supernatant was 
collected for the measurements of A: total cholesterol and B: triglyceride levels.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin. *P<0.05 compared to diabetic control, 
#P<0.05 compared to lean control. 
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3.2.7 CGA decreases oil droplets formation in HepG2 Cells 
In line with the in vivo findings, CGA or metformin reduced the formation of oil 
droplets in HepG2 cells. In the vehicle-treated cells, the oil droplets were big and 
obvious (arrow) while in CGA- or metformin-treated cells, the oil droplets were 
smaller and less dense (Figure 3.2.10 A). There was a decrease of 37.8% in the OD of 
eluted dye from CGA-treated cells, compared to vehicle-treated cells (Figure 3.2.10 
B). 
3.2.8 Amelioration of hepatic lipid accumulation by CGA is mediated through 
inhibition of fatty acid synthesis 
All of the above data suggested that at least one of the intermediary building-blocks 
for the synthesis of a more complex lipid molecule in the liver was reduced by the 
treatment with CGA or metformin. Therefore, the present authors examined the effect 
of CGA on fatty acid synthesis in HepG2 cells. Inhibition of fatty acid synthesis as 
measured by the incorporation of 
14
C-acetate into fatty acids was observed in CGA- or 
metformin-treated hepatocytes. CGA inhibited fatty acid synthesis in a dose- (Figure 








    




A: Fixed HepG2 cells were stained with Oil Red O in 60% isopropanol for ten 
minutes at room temperature. Accumulation of fat droplets was examined under 
inverted light microscope (scale bar = 25µm). B: Quantitation was done by eluting the 
stain with 100% isopropanol.  OD was measured at 500nm  
Images shown are representative of the corresponding treatment group. DC=Diabetic 







    
Figure 3.2.11. CGA inhibits fatty acid synthesis in HepG2 cells 
 
 
Treated HepG2 cells were incubated with 
14
C-sodium acetate (2µCi/ml) for 4 hours at 
37ºC. Cells were lysed and radioactivity incorporated into fatty acid was monitored 
using scintillation counter. Readings were expressed as percent inhibition of fatty acid 
synthesis compared to control.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 
**P<0.01 compared to vehicle-treated control. 
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Skeletal muscles isolated from Lepr
db/db
 mice showed significant increase in glucose 
transport after treated with CGA (Figure 3.2.12). CGA (2 mmol/l) increased the 
glucose transport of myotubes by 48±13% and the stimulation continued to increase 
and achieve stability at higher concentrations. No significant difference in glucose 
transport was observed between lean mice and diabetic mice. However, a significant 
decrease of 54±3% in insulin-stimulated glucose transport was shown in diabetic mice 
compared to lean mice. CGA treatment further enhanced the insulin-mediated glucose 












    






Skeletal muscles were isolated from Lepr
db/db
 mice and treated with CGA or/ and 100 
nmol/l insulin or 2 mmol/l metformin for 30 minutes. 2-deoxyglucose uptake was 
measure over a 30-minute period, using liquid scintillation counter.  
Data were expressed as the mean ± SE of three independent experiments. 
DC=Diabetic Control, DMet=Diabetic treated with metformin, D(0.5, 1, 2, 4, 8, 
10)=Diabetic treated with various concentrations of CGA. *P<0.05, **P<0.01 
compared with controls. DC=Diabetic Control. 
 
3.2.10 Chronic treatment with CGA increases glucose uptake in skeletal muscles 
by increasing GLUT 4 expression and translocation to plasma membrane 
GLUT is a superfamily of genes, encoding homologous proteins with different 
functional properties and tissue-specific expressions [145]. Glucose transport is 
mediated by the members of GLUT protein family, which consists of 12 
transmembrane transporters [146]. GLUT 4 is exclusively expressed in peripheral 
insulin-sensitive tissues like fat, skeletal and cardiac muscles. It is the only insulin-
responsive GLUT identified so far, with the observation that its level of expression in 
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various muscles and fat cells generally corresponded to the magnitude of insulin-
stimulated glucose disposal in the tissues [147]. Later on, it was established that this 
insulin-stimulated glucose transport was mediated through the redistribution of GLUT 
4 from the intracellular membrane compartment to the cell surface [148]. 
Expression of GLUT 4 and translocation of GLUT 4 to plasma membrane of skeletal 
muscles were dramatically decreased in Lepr
db/db
 mice, as shown by 
immunohistochemistry staining, compared to normal lean mice (Figure 3.2.14A-D). 2 
weeks of treatments with CGA or metformin sinificantly elevated the expression and 
translocation of GLUT 4, as depicted by the increase in stained GLUT 4 in both 
intracellular and plasma membrane compartments of the skeletal muscles. To further 
corroborate these findings, the present authors quantitated the amount of GLUT 4 
protein from both whole tissue lysate and fractionated plasma membrane of the 
skeletal muscles using immunoblotting. Consistently, GLUT 4 content was lower in 
both whole tissue lysate and plasma membrane fraction in vehicle-treated Lepr
db/db
 
mice, suggesting insulin resistance in skeletal muscle. However, treatment with CGA 
or metformin significantly increased the expression and translocation of GLUT 4 
(Figure 3.2.14E). We next examined the effect of CGA on glucose transport in the 
skeletal muscles to provide further confirmatory evidence for the stimulatory effect of 
CGA on GLUT 4 expression and translocation. Consistent with decreased plasma-
membrane GLUT 4 available for glucose transport into skeletal muscles of Lepr
db/db
 
mice, glucose uptake by the tissues were significantly lower, compared to lean control 
(Figure 3.2.13). In addition, exogenous insulin failed to stimulate glucose transport 
into these tissues, indicating insulin resistance. As expected, increased plasma-
membrane GLUT 4 by CGA caused a rise of 67.9% in glucose transport of skeletal 
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muscles, compared to vehicle-treated skeletal muscles. In the presence of insulin, 
CGA caused a more than 2.5-fold increase in glucose transport in skeletal muscles, 
compared to vehicle-treated control, suggesting an additive effect of CGA treatment 
to insulin action (Figure 3.2.13). 




Skeletal muscles isolated from Lepr
db/db
 mice after 2 weeks of treatments were 
incubated with 0.5 ml KRBB containing 1 µCi/ ml 2-Deoxy-[
3
H]D-glucose for 30 
minutes at 37ºC. Quatitation of 2DG taken up by the tissue was performed using 
liquid scintillation counter. Readings were expressed as nmol 2DG uptake per mg 
tissue in one minute.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 




    
Figure 3.2.14. Chronic CGA treatment increases GLUT 4 expression and 





A: Skeletal muscle sections were stained with DAPI for nuclear staining. Images were 
captured using fluorescence microscope (scale bar = 50µm).  
Images shown are representatives of the corresponding treatment group from three 







    
 
 
B: Skeletal muscle sections were incubated with and anti-e-cadherin (plasma 
membrane marker) overnight at 4ºC before staining with Alexa Fluor 555-conjugated 
mouse IgG secondary antibody.  
Images were captured using fluorescence microscope (scale bar = 50µm). Images 
shown are representatives of the corresponding treatment group from three 









    
 
 
C: Skeletal muscle sections were incubated with anti-GLUT 4 overnight at 4ºC before 
staining with FITC-conjugated rabbit IgG secondary antibody. Images were captured 
using fluorescence microscope (scale bar = 50µm).  
Images shown are representatives of the corresponding treatment group from three 










    
 












    
 
E: GLUT 4 was quantitated in total cell lysate and plasma membranes fractionated 
from skeletal muscles of Lepr
db/db
 after treatments for 2 weeks, using immunoblotting.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 




    
3.2.11 Dose- and time-dependent stimulation of glucose transport by CGA in L6 
myotubes 
In order to strengthen our in vivo findings, the present authors next investigated the 
effects of CGA on glucose transport in L6 myotubes. Treatment of myotubes with 
increasing concentrations of CGA for 24 hours led to a significant dose-dependent 
increase in glucose transport, which was first observed at 1 mmol/l (55±8%). The 
highest increase was observed at 2 mmol/l (63±6%) and the stimulation was 
maintained up to the highest concentration tested, which was 10 mmol/l (Figure 
3.2.15A). Besides, a time-dependent stimulation of glucose transport was also 
observed when myotubes were incubated with 2 mmol/l CGA at different incubation 
periods. Significant increase was first observed after 1-hour incubation (14±1%), and 
continued to increase to 60±5% after 24 hours of incubation (Figure 3.2.15B). In all 
subsequent experiments, the effects of CGA were determined at a concentration of 2 









    
Figure 3.2.15.  Dose- and time-dependent stimulation of glucose transport in L6 
myotubes by CGA.  
 
 
A: L6 myotubes were incubated with incremental concentrations of CGA for 24 hours. 
B: L6 myotubes were incubated with 2 mmol/l CGA at different incubation periods up 
to 24 hours. 2-deoxyglucose uptake was measure over a 30-minute period, using 
liquid scintillation counter.  
Data were expressed as percentage increase over basal uptake of cells incubated with 
vehicle. Data were expressed as the mean ± SE of three independent experiments. 
*P<0.05, **P<0.01 compared with vehicle-treated control. 
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3.2.12 CGA stimulates GLUT 4 translocation to plasma membrane in L6 
myotubes 
From our in vivo study, the present author knows that simulation of glucose transport 
in skeletal muscles by CGA was associated with increased GLUT 4 expression and 
translocation to plasma membrane. He therefore investigated whether the glucose 
transport in response to CGA in L6 myotubes was accompanied by an increase in 
expression and translocation of the GLUT 4 to the plasma membrane of myotubes. 
Also, in this in vitro model, he investigated the effect of CGA on another GLUT 
member, GLUT 1. The broad distribution of GLUT 1makes it an important 
transporter regulating the basal glucose disposal. Its expression has been shown to be 
altered by sulfonylureas [149], insulin [150], hypoxia [151], insulin-like growth 
factor-1[152] and a number of other factors. Treatment of myotubes with CGA for 
different time periods augmented GLUT 4 content on plasma membrane of myotubes, 
with the significant increase first observed at 1-hour incubation, increasing in a time-
dependent manner for up to 24 hours (Fig 3.2.16B). Metformin demonstrated a similar 
increase in GLUT 4 on plasma membrane of myotubes. However, neither metformin 
nor CGA caused significant changes in total GLUT 4 expression or plasma 






    
Figure 3.2.16.  CGA stimulates GLUT 4 translocation to plasma membrane in 
myotubes 
 
Myotubes were treated with 2 mmol/l CGA for various incubation periods up to 24 
hours. A: Whole cell lysate was used to detect for GLUT 4 and GLUT 1 expression 
through immunoblotting. Illustrated are the representative images of three 
independent experiments.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 




    
 
Myotubes were treated with 2 mmol/l CGA for various incubation periods up to 24 
hours. B: isolated plasma membranes were used to detect for amount of GLUT 4 or 
GLUT 1 translocated through immunoblotting. Illustrated are the representative 
images of three independent experiments.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 
**P<0.01 compared with controls. 
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3.3 Studies of molecular pathways that mediate beneficial metabolic 
effects of CGA 
3.3.1 CGA increases AMPK and ACC phosphorylations in response to Ca2+ 
influx in HepG2 hepatoma cells 
In HepG2 cells, CGA induced AMPK phosphorylation in a time- (Figure 3.3.1A) and 
dose-dependent (Figure 3.3.1B) manner. AMPK immnunoprecipitated from treated 
cells were evaluated for its kinase activity against SAMS peptide and it showed that 
CGA activated and increased AMPK activity in a similar manner (Figure 3.3.1C-D). 
To further elucidate its activation by CGA, the present author investigated the effect 
of CGA on its downstream substrate, ACC. Increased ACC phosphorylation 
correlated with AMPK activation was observed in both treatments with CGA or 
metformin (Figure 3.3.1A-B). Since AMPK activation inhibits ACC activity, we 
observed decreases in ACC activities in response to CGA or metformin treatments 
(Figure 3.3.1E-F), and therefore it is evident that CGA or metformin induced 
activation of AMPK but inhibited ACC. Several upstream signaling were known to 
phosphorylate AMPK such as cellular stress that causes a fall in ATP: AMP ratio 
[153], tumor suppressor kinase LKB-1 [154] and CaMKK [155]. He showed that 
activation of AMPK by CGA was mediated by CAMKKβ in HepG2 hepatoma 
cells(Figure 3.3.1A-B). In addition, we further demonstrated that treatment of HepG2 
hepatoma cells with CGA resulted in an increase in the intracellular Ca
2+ 
concentration measured by Fluo-4 (Figure 3.3.1G-H), suggesting that CGA caused 
influx of extracellular Ca
2+ 
into hepatoma cells, thereby activating CAMKK which in 
turn phosphorylated AMPK. 
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Figure 3.3.1. CGA increases AMPK and ACC phosphorylations in response to Ca
2+ 
influx in HepG2 hepatocytes.  
 
 
A: Treated HepG2 cells in various incubation periods were lysed for the quantitation 
of pAMPK, total AMPK, pACC, total ACC and CAMKK using immunoblotting. 
Phosphorylated proteins were adjusted to total proteins while CAMKK was adjusted 
to GAPDH.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 




    
 
 
B: Treated HepG2 cells with various CGA concentrations were lysed for the 
quantitation of pAMPK, total AMPK, pACC, total ACC and CAMKK using 
immunoblotting. Phosphorylated proteins were adjusted to total proteins while 
CAMKK was adjusted to GAPDH.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 





    
 
 
C-D: Treated cells were lysed and immunoprecipitated with anti-AMPK α1/2 
antibody. Kinase reaction was initiated against SAMS peptides in the presence of γ-
ATP. Radioactivity was measured using liquid scintillation and kinase activity was 
expressed as incorporated ATP/mg protein/minute.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 




    
 
 
E-F: Treated cells were lysed and assayed against NaH
14
CO3 for 40 minutes at room 
temperature. Total 
14
C incorporated was measured using liquid scintillation counter 
and ACC activity was expressed as incorporated 
14
C /mg protein/minute. G-H: 
Treated cells were incubated with equal volume of 2 X Fluo-4 Direct calcium reagents 
for one hour at 37˚C. Fluorescence was measured at 494 nm (excitation) and 516 nm 
(emission).  
Readings were expressed as % increase in free calcium influx compared to vehicle-
treated cells. Data were expressed as the means ± SE of three independent 
experiments. DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. 
*P<0.05, **P<0.01 compared to vehicle-treated control. 
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G-H: Treated cells were incubated with equal volume of 2 X Fluo-4 Direct calcium 
reagents for one hour at 37˚C. Fluorescence was measured at 494 nm (excitation) and 
516 nm (emission). Readings were expressed as % increase in free calcium influx 
compared to vehicle-treated cells.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 
**P<0.01 compared to vehicle-treated control. 
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3.3.2 Chronic treatment with CGA increases phosphorylations of AMPK and 
ACC and expression of CAMKKβ in liver and skeletal muscles of Leprdb/db 
mice 
Leptin has been shown to stimulate phosphorylation of AMPK  in skeletal muscles 
through elevation of AMP levels in the muscles [156]. The present author's data 
showed that in this leptin-signaling deficient model, phosphorylation of AMPK was 
significantly lowered in both liver and skeletal muscles, compared to NC (Figure 
3.3.2), consistent with previous proposal that there is a close association between  
AMPK activation and leptin sensitivity [157]. Two-week treatment with CGA or 
metformin increased  phosphorylation of AMPK in the liver and skeletal muscles of 
the animals, which in turn resulted in increased phosphorylation of  its downstream 
substrated, ACC. Consistently, CGA was found to increase expression of CAMKKβ 
in the animal but metformin did not significantly increase its expression, indicating 
CGA and metformin may activate AMPK via two different upstream  regulators. 
Interestingly, for the first time, he observed a decreased CAMKKβ expression in this 
leptin receptor-deficient model, creating a question whether disruption in leptin 







    
Figure 3.3.2. Chronic CGA administration phosphorylates AMPK and ACC in liver 





A: At the end of the treatment, liver were collected and homogenized to quantitate for 
pAMPK, total AMPK, pACC, total ACC and CAMKK using immunoblotting. 
Phosphorylated proteins were adjusted to total proteins while CAMKK was adjusted 
to GAPDH.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 
**P<0.01 compared to vehicle-treated control. 
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B: At the end of the treatment, isolated skeletal muscles were collected and 
homogenized to quantitate for pAMPK, total AMPK, pACC, total ACC and CAMKK 
using immunoblotting. Phosphorylated proteins were adjusted to total proteins while 
CAMKK was adjusted to GAPDH.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. *P<0.05, 
**P<0.01 compared to vehicle-treated control. 
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3.3.3 Inhibition and knockdown of AMPK abolished CGA-inhibited 
gluconeogenesis and fatty acid synthesis in HepG2 cells 
The present author next examined whether AMPK is responsible for the inhibition of 
hepatic gluconeogenesis and fatty acid synthesis by CGA. As predicted, inhibitory 
effects of CGA on glucose production and fatty acid synthesis were abolished by pre-
incubation with the AMPK inhibitor, compound c (Figure 3.3.3B&C).  Also, AMPK 
knockdown by using siRNA almost completely abrogated CGA-mediated inhibition 
of glucose production and fatty acid synthesis in HepG2 hepatoma. Besides, CAMKK 
selective inhibitor, STO-609, resulted in similar effect on the inhibition of glucose 
production and fatty acid synthesis by CGA. Taken together, in vivo or in vitro, he 
provided evidence that AMPK is vital for the action of CGA on hepatic glucose and 
lipid metabolism. 
3.3.4 CGA stimulates phosphorylations of AMPK and ACC in L6 myotubes 
AMPK activation has been associated with increased GLUT 4 translocation to plasma 
membrane and enhanced glucose transport [158, 159]. The present author has shown 
that AMPK is vital for CGA to inhibit hepatic glucose production and fatty acid 
synthesis in HepG2 hepatoma. Likewise, long-term administration of CGA in 
Lepr
db/db 
mice resulted in phosphorylations of AMPK and ACC in animal skeletal 
muscles.
 
Thus, to further show that AMPK plays an important role in CGA-mediated 
glucose transport in skeletal muscle, he evaluated the effect of CGA on AMPK and 
ACC phosphorylations in L6 myotubes. Like metformin, CGA increased AMPK 
phosphorylation and also ACC phosphorylation in a time- (Figure 3.3.4A) and dose-
dependent (Figure 3.3.4B) manners. In addition, AMPK activity was increased time- 
and dose-dependently also by CGA and therefore explaining its phosphorylation 
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stimulated by CGA (Figure 3.3.5A&B). In line with our findings in vivo, activation of 
AMPK by CGA was also mediated by CaMKK in L6 myotubes (Figure 3.3.4A & 5B). 
Figure 3.3.3. Inhibition and knockdown of AMPK abolished CGA-inhibited 
gluconeogenesis and fatty acid synthesis 
 
A: HepG2 cells were transfected with AMPK α1/2 siRNA using oligofectamine. B: 
Cells pre-treated with inhibitors or siRNA were incubated with CGA to study possible 
mediator(s) for CGA-inhibited glucose production.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. **P<0.01 
compared to CGA-treated control. 
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C:  Cells pre-treated with inhibitors or siRNA were incubated with CGA to study 
possible mediator(s) for CGA-inhibited fatty acid synthesis.  
Data were expressed as the means ± SE of three independent experiments. 
DC=Diabetic Control, Met=Metformin, Veh=vehicle-treated control. **P<0.01 







    




A: Myotubes were treated with CGA for various incubation periods. Whole cell lysate 
was used for the detection of p-AMPK, AMPK, p-ACC, ACC and CaMKKβ. 
Phosphorylated proteins were adjusted to respective total protein while CAMKK was 
adjusted to GAPDH.  
Illustrated are the representative images of three independent experiments. Data were 
expressed as the mean ± SE of three independent experiments. *P<0.05, **P<0.01, 




    
 
B: Myotubes were treated with CGA in various concentrations. Whole cell lysate was 
used for the detection of p-AMPK, AMPK, p-ACC, ACC and CaMKKβ. 
Phosphorylated proteins were adjusted to respective total protein while CAMKK was 
adjusted to GAPDH.  
Illustrated are the representative images of three independent experiments. Data were 
expressed as the mean ± SE of three independent experiments. *P<0.05, **P<0.01 
compared with controls. 
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Figure 3.3.5.  CGA increases AMPK activity in L6 myotubes 
 
 
A: Myotubes were treated with 2 mmol/l CGA for various incubation periods up to 24 
hours. B: Myotubes were treated with 2 mmol/l CGA for various incubation periods 
up to 24 hours.  Whole cell lysate was immunoprecipitated with anti-AMPK α1/2. 
Immunoprecipitate was assayed against SAMS peptide in the presence of [γ-32P]ATP. 
kinase activity was expressed as incorporated ATP/mg protein/minute.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 
**P<0.01, compared with controls. 
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3.3.5 Compound c diminishes glucose transport stimulated by CGA in L6 
myotubes 
Previously, the present author has observed inhibitory effects of compound c on 
CGA-mediated inhibition of hepatic glucose and fatty acid synthesis (Section 3.3.3). 
To explain the mechanism underlying the glucose transport stimulated by CGA, he 
examined the effect of several molecules which are capable of mediating the 
stimulation of glucose transport. Wortmannin is a well-known selective inhibitor for 
PI3K, a key regulator in insulin signaling [160]. Pretreatment of myotubes with 100 
nmol/l wortmannin for 30 minutes abolished the stimulatory effect of insulin on 
glucose transport (Fig. 3.3.6A). However, no effect was observed with the 
wortmannin pretreatment on CGA-stimulated glucose transport. CGA further 
increased insulin-stimulated glucose transport its glucose transport up to 100±2%, 
suggesting that CGA may not work on the insulin-dependent pathway. Moreover, 
pretreatment of CGA and insulin-stimulated transport with wortmannin only partially 
inhibited the stimulation but not to the extent of that obtained in insulin-only-
stimulated transport. Hence, to investigate whether CGA acts through the insulin-
independent pathway, he examined the effect of compound c, a selective inhibitor of 
AMPK [161, 162], on the CGA-stimulated glucose transport. Pretreatment with 10 
µmol/l compound c for 30 minutes significantly abated the glucose transport 





    




A: L6 myotubes were incubated with 2 mmol/l CGA for 24 hours. A: Myotubes were 
preincubated with 100 nmol/l wormannin for 30 minutes before incubated with CGA 
or insulin. Myotubes were then incubated with 100 nmol/l insulin (30 minutes) or 2 
mmol/l metformin (2 hours) or 2mmol/l CGA (4 hours) before 2DG uptake 
measurement. 2DG uptake was measured over a 30-minute period using liquid 
scintillation counter. Readings are expressed as percentage increase over basal uptake 
of cells incubated with vehicle.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 
**P<0.01, compared with controls. 
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B: L6 myotubes were incubated with 2 mmol/l CGA for 24 hours. A: Myotubes were 
pre-incubated with 10 μmol/l compound c for 30 minutes before incubated with CGA 
or insulin. Myotubes were then incubated with 100 nmol/l insulin (30 minutes) or 2 
mmol/l metformin (2 hours) or 2mmol/l CGA (4 hours) before 2DG uptake 
measurement. 2DG uptake was measured over a 30-minute period using liquid 
scintillation counter. Readings are expressed as percentage increase over basal uptake 
of cells incubated with vehicle.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 
**P<0.01, compared with controls. 
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3.3.6 AMPK is necessary for the glucose transport stimulation by CGA in L6 
myotubes 
Besides using inhibitor compound c, AMPKα content was reduced with RNA 
silencing. AMPKα 1/2 siRNA nucleotides reduced the total expression of AMPKα 1/2 
by 74±7% compared with transfection with equal concentration of unrelated control 
siRNA sequence (Fig 3.3.7A). Transfection with AMPKα 1/2 or unrelated siRNAs 
alone did not affect glucose transport. However, reduction in total expression of 
AMPKα 1/2 significantly reduced glucose transport stimulated by CGA by 58±5% 
(Fig 3.3.7B). Unrelated control siRNA did not significantly affect CGA-stimulated 
glucose transport, though a slight increase was detected. Taken together, the data 












    
Figure 3.3.7.  Effects of gene silencing of AMPK on CGA-stimulated glucose 
transport in L6 myotubes 
 
L6 myotubes were transfected with vehicle, unrelated siRNA or AMPKα1/2. A: 
Expression of AMPKα1/2 after transfection with or without unrelated siRNA or 
AMPKα1/2 siRNA. B: Transfected or non-transfected myotubes were incubated with 
2 mmol/l CGA for 24 hours. 2DG uptake was measure over a 30-minute period using 
liquid scintillation method. Readings were expressed as percentage increase over 
basal uptake that was obtained from non-transfeted cells incubated with vehicle.  
Data were expressed as the mean ± SE of three independent experiments. **P<0.01 
compared with non-transfected-control treated with CGA. 
121 
    
3.3.7 CGA does not induce association of p85 subunit of PI3K to IRS-1 in L6 
myotubes 
Activation of PI3K requires association of its p85 subunit to IRS-1 as shown by 
insulin in Fig 3.3.8C. However, CGA did not produce any significant effect on the 
association of p85 to IRS-1 immunoprecipitates of myotubes compared to the 
association observed in vehicle-treated myotubes. This again suggests that the 
stimulatory effect of CGA on glucose transport may not be attributable to PI3K 
activation. To further examine whether CGA activates the PI3K-Akt pathway, the 
present author investigated the effect of CGA on Akt phorphorylation. Surprisingly, 
he observed that Akt was phosphorylated at Thr 308 by insulin as well as CGA (Fig 
3.3.8D). 
3.3.8 Effect of CGA on L6 myotubes viability and proliferation 
To discard the possibility that increases in glucose transport in response to CGA 
might be due to the changes in myotube numbers, the present author assessed the 
effect of increasing doses of CGA on cell viability and cell proliferation. No 
significant changes were observed up to a concentration of 4 mmol/l (Fig 3.3.9A). 
However, significant increases in cell death were observed at 6 mmol/l (17.4±5%), 8 
mmol/l (19.9±4%) and 10 mmol/l (17.6±4%) compared to vehicle-treated myotubes. 
On the other hand, myotubes treated with different concentrations of CGA did not 
produce any significant changes in all three cell-cycle phases, G0/G1, S and G2/M, 
compared to the vehicle-treated myotubes (Fig 3.3.9B). Taken together, at the 
concentration of 2 mmol/l, CGA did not cause significant cell death or cell-cycle 
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arrest, thus eliminating the possibility that cell numbers may affect the study of 
glucose transport. 
 
Figure 3.3.8.  CGA phosphorylates Akt in the absence of PI3K in L6 myotubes 
 
A: Myotubes were treated with vehicle, 100 nmol/l insulin or 2 mmol/l CGA. Whole 
cell lysate was immunoprecipitated with IRS-1 and immunoblotted for IRS-1 and p85 
subunit of PI3K. B: Myotubes were treated with vehicle, 100 nmol/l insulin or 2 
mmol/l CGA. Whole cell lysate was detected for p-Akt through immunoblotting.  
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Data were expressed as the mean ± SE of three independent experiments. *P<0.05, 




Figure 3.3.9.  Effects of CGA on cell viability and cell proliferation of L6 myotubes 
 
 
A: Myotubes were incubated with incremental concentrations of CGA for 24 hours. 
Viability of myotubes was measured using MTT staining. Readings are expressed as a 
percentage of non-viable cells compared to vehicle-treated myotubes.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05 
compared with vehicle-treated control. 
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B: Myotubes were incubated with incremental concentrations of CGA for 24 hours. 
Numbers of cells in cell-cycle phases were examined using propidium iodide staining 
and FACS analysis. Readings are expressed as percentage of cells stained by 
propidium iodide at different phases.  
Data were expressed as the mean ± SE of three independent experiments. *P<0.05 
compared with vehicle-treated control. 
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4 Discussion 
The global prevalence of diabetes mellitus has been increasing dramatically due to the 
fact that globalization has led to social impacts such as urbanization and lifestyle 
changes [163]. Diabetes, especially T2DM, previously thought to be prevalent in 
developed countries [164], has now emerged as a potential epidemic in developing 
countries like China and India [165]. T2DM was once believed to be a metabolic 
syndrome exclusive to adults, but has now risen as a plague in adolescents and also 
children [166]. In 2010, an estimated 285 million cases of diabetes were reported; this 
figure is expected to increase by 54% to 439 million by 2030 [165]. Despite the 
availability of a variety of pharmacological agents to control blood glucose level 
(from insulins, sulfonylureas, biguanides, thiazoledinediones to the most-recent DPP 
IV), lifestyle changes involving exercise and dietary intervention are pivotal to 
achieving the goal of cost-effective management with minimal complications but 
maximal quality of life. This is because pharmacological management of diabetes is 
always associated with unwanted side effects and incapability of human nature in 
adhering to sustaining exercise regimen as discussed in Section 1.5. Therefore, dietary 
intervention becomes the most powerful tool to combat and keep the disease at bay. 
Polyphenol-rich coffee and other plant-based foods like Vernonia amygdalina are 
always associated with improved glycemic responses (Section 1.6 & 1.71). It is thus 
imperative to learn what is/are the component(s) in these foods that cause this 
beneficial metabolic changes and how they work in order to manage the disease in a 
more efficient and cost-effective manner. 
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4.1 Studies on the antidiabetic effects of VA 
In the beginning of the present study, the author started with the investigation on the 
anti-diabetic effects of VA and its possible mechanisms of action, at the same time 
identifying the bio-constituents that are responsible for the biological activities. The 
potential health benefits of VA remain anecdotal until Kupchan et al. demonstrated 
that chloroform fraction of VA contains compounds which are toxic to cancerous cells 
in vitro[167]. Since then, several active molecules, belonging to the family of 
sesquiterpene lactones, such as vernomygdaline, vernolide, vernodaline and 
vernolepin, were identified as potential anticancer agents [168]. The present study 
focused on identifying possible active constituents from more polar fraction, in the 
hope that they would be less toxic but possessing beneficial health effects. Four main 
polyphenols were identified in the ethanolic VA extract. They are dicaffeoyl quinic 
acid, 1,5-dicaffeoyl-quinic acid, chlorogenic acid and luteolin-7-O-glucoside. 
Dicaffeoyl quinic acid and its isomers appear to be the most abundant compounds 
present in the extract. These findings are consistent with the study by Ola et al. (2009) 
[136].  In an acute glucose tolerance test, 400 mg/kg of VA exerted the most effective 
anti-hyperglycemic activity. This effective dose is similar to that reported in previous 
studies [86, 88]. A 28-day chronic study revealed that VA significantly decreased 
fasting blood glucose. Both of these designs demonstrated the anti-diabetic efficiency 
of VA and supported the findings of previous studies [84-86, 88, 95]. 
STZ (2-deoxy-2(3-methyl-3-nitrosoureido)-D-glucopyranose) is a nitrosourea widely 
used to induce experimental diabetic animal model. Its glucose moiety is responsible 
for STZ to be transported into insulin-secreting β-cells via GLUT 2 [169] while the 
nitrosoamide moiety is accounted for the toxicity of this compound [170].  The 
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mechanism of cytotoxicity of STZ on β-cells were extensively reviewed by 
Szkudelski et al. [131]. STZ-induced diabetes is characterized by hypoinsulinemia, 
polydipsia, polyuria and decreased body weight [171]. Several other abnormalities 
like increased activities of alkaline phosphatase, aspartate transaminase, alanine 
transaminase and changes in the activities of several enzymes in carbohydrate 
metabolism were also observed in this model [172, 173]. Impairment in the 
antioxidant defence was also reported in this model. Lipid peroxides, hydroperoxides 
and protein carbonyls are significantly higher in plasma, pancreatic tissue and kidney 
of these animals; activities of antioxidant enzymes such as superoxide dismutase, 
catalase, glutathione peroxidase and glutathione-S-transferase were found to be lower 
in plasma, pancreas and kidney [174, 175].  
Treatment with metformin or VA greatly improved polyuria and polydipsia (Table 
3.1.1), indicating improvement in the diabetic conditions. Currently available oral 
hypoglycemic drugs such as sulfonylureas and thiazolidinediones often lead to weight 
gain, which is an unwanted side effect that will further promote insulin resistance [56]. 
In this study, both metformin and VA caused significant improvements in body 
weight, suggesting that they may be better candidates for combating diabetes, 
especially T2DM. Moreover, there were neither significant changes in food intake nor 
any sign of toxicity. VA possessed anti-lipidemic activity, in accord with 
Adaramoye’s study which also showed its lipid-lowering effect [176]. Several 
previous studies proposed that VA possibly acted through stimulating insulin 
secretion from pancreatic β-cells [84, 86, 88, 92]. In spite of the fact that we observed 
significant increase in insulin level in VA-treated animals, the insulin levels in STZ-
diabetic rats are negligible if compared to normal control. This might be due to 
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immense loss of pancreatic β-cells as a result of toxicity from a single high-dose STZ. 
Also, another study has shown that β-cells isolated from STZ-treated animal are 
almost completely unresponsive to stimulation by glucose or sulfonylureas [177]. In 
some studies, co-administration of nicotinamide was performed in STZ-induced 
diabetic animal in order to prevent excessive depletion of insulin secretion [178, 179]. 
Further investigations are needed to clarify whether VA stimulates insulin secretion. 
Physiological levels of reactive oxygen species (ROS) are essential for cell 
proliferation and regulation of cell signaling. Oxidative stress occurs when our body 
loses its ability to maintain redox homeostasis such that the generation of ROS 
exceeds their utilization, neutralization and elimination. In diabetes, the generation of 
ROS is greatly increased due to glucose auto-oxidation and lipid peroxidation. 
Excessive ROS results in tissue damage and subsequent diabetic complications 
against which our conventional hypoglycemic drugs appear to be ineffective.  Our 
body’s first-line anti-oxidative defense consists of enzymatic (SOD, catalase, GPx) 
and non-enzymatic (glutathione) antioxidants. SOD accelerates dismutation of O2
-
 to 
H2O2, while catalase and GPx catalyze the conversion of H2O2 to H2O. VA resulted in 
up-regulation of antioxidant enzymes, especially GPx and glutathione. These effects 
may all be due to the high polyphenolic content of the extract. Several studies showed 
that polyphenols modulate promoter activities of several antioxidant enzymes and this 
may be due to the activation of antioxidant/electrophile responsive elements 
(AREs/EpREs) [180]. Further study is required to determine how VA polyphenols, 
especially dicaffeoyl-quinic acids, regulate the activities of antioxidant enzymes. 
As discussed before, GLUT 1 (non insulin-responsive) and GLUT 4 (insulin-
responsive) are two major glucose transporters that regulate glucose uptake into 
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various tissues. GLUT 1 is expressed ubiquitously while GLUT 4 is mainly expressed 
in skeletal muscles and adipocytes. STZ was reported to affect expression of GLUT 4 
[181-184] but not GLUT 1 [182]. Our results showed a similar effect. We further 
assessed GLUT 4 translocation to plasma membrane and found that rats treated with 
STZ have most of their GLUT 4 retained in the light microsomal membrane while the 
functional GLUT 4 on plasma membrane was significantly decreased. Treatment with 
metformin or VA increased both total GLUT 4 expression and likewise the functional 
plasma membrane GLUT 4. This observation is further strengthened by the finding of 
increase in muscle glycogen synthesis which is consistent with the finding of 
increased muscle glucose uptake regulated by GLUT 4. Metformin has been shown to 
modulate GLUT 4 translocation through the AMPK pathway [29, 185]. Further 
investigations are needed to characterize the pathway by which VA increased both 
GLUT 4 expression and translocation.  
G6Pase is one of the rate-limiting gluconeogenic enzymes that regulate glucose 
synthesis. Due to insulin deficiency from β-cell loss caused by STZ, activation of 
G6Pase was observed [186]. Metformin is well-known for its antigluconeogenic 
property [187] and our results again showed its strong suppression of G6Pase activity. 
On the other hand, VA also exerted some degree of inhibition of G6Pase activity. The 
limitation of this study is that variations in insulin level could be a confounding factor.  
VA caused a slight increase in insulin which can, in turn, increase translocation of 
GLUT 4 and glycogenesis while inhibiting gluconeogenic enzymes such as G6Pase. It 
appears that other diabetic models in which insulin levels are constant should be 
employed to further confirm these findings. 
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4.2 Studies on the antidiabetic effects of CGA 
As discussed in Section 1.7.2, most of the studies involving CGA and its antidiabetic 
effects were associated with regulation of fasting and postprandial glucose levels, 
which were attributable to the inhibition of gluconeogenesis, increased peripheral 
glucose uptake and reduced intestinal glucose absorption. None of these studies has 
suggested that CGA may stimulate insulin secretion from pancreatic β-cells. Hence, 
we strongly believe that CGA may have a greater impact on T2DM rather than T1DM. 
As a result, the animal model which the present author next used for the study of CGA 
is a genetically-induced T2DM model, known as Lepr
db/db 
mice.  Leptin is the primary 
adipose hormone that conveys adiposity signal to the brain. The brain, particularly the 
hypothalamus, integrates leptin and various other metabolic signals to regulate energy 
homeostasis and body weight by controlling both behavioral and metabolic responses 
[188]. Leptin decreases body weight by suppressing appetite and by increasing energy 
expenditure [189-191]. This mutant species is leptin receptor-deficient. This genetic 
deficiency of leptin receptors results in obesity and obesity-associated metabolic 
changes (detailed metabolic changes was discussed previously in Section 1.7.4) which 
closely resembles human T2DM [192, 193]. 
Acute administration of CGA significantly lowered fasting blood glucose in a genetic 
T2DM model, Lepr
db/db
 mice. However, reduction in fasting glucose level cannot be 
explained by the delay in intestinal glucose absorption. Moreover, it has been shown 
that CGA suppressed G6Pase activity [114, 119], suggesting a possible role of CGA 
on gluconeogenesis. Yet, no study has been conducted to investigate its direct effect 
on hepatic glucose production. Thus, for the first time, the present author 
demonstrated its inhibitory effect on glucose production in HepG2 cells. Concurrent 
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inhibition of the expression of G6Pase was observed with the decreased glucose 
production by CGA. We believe that although its duration of acute action in 
suppressing glucose levels during the OGTT is relatively short, compared to 
metformin, long-term consumption of CGA may be beneficial as with coffee 
consumption.  As predicted, 2-week treatment with CGA decreased fasting blood 
glucose and insulin levels. In addition, glucose and insulin tolerance of the animals 
were also significantly improved. He further assessed its long-term effect on 
gluconeogenesis in vivo, via PTT, as administration of gluconeogenic substrate 
pvruvate increased blood glucose by stimulating gluconeogenesis in the liver. CGA 
attenuated pyruvate-induced hyperglycemia, indicating reduced gluconeogenesis, 
which is in agreement with decreases in the expression and activity of G6Pase in the 
liver. 
One might postulate the dysregulation of gluconeogenesis is attributed to the 
impairment in insulin secretion which is commonly found in patients with impaired 
glucose tolerance or complete glucose intolerance and CGA may have stimulatory 
effect on insulin secretion. However, in this diabetic animal model, the present author 
observed fasting hyperinsulinemia, which is commonly associated with obesity and 
insulin resistance [42]. Treatment with CGA, on the other hand, ameliorated 
hyperinsulinemia. Significantly lower AUCglucose as well as AUCinsulin, improved 
insulin tolerance and HOMAIR index by CGA further explain and suggest its insulin 
sensitizing role, which may explain the paradoxical effect of coffee on glucose 
intolerance and insulin resistance in T2DM [103, 194, 195]. 
There is no previous study to implicate CGA to peripheral glucose disposal until 
Prabhakar and Doble (2009) showed for the first time that CGA stimulated glucose 
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transport in myotubes via increased expression of GLUT 4 and PPAR-γ transcript 
[128]. However, mere increase in GLUT 4 gene expression cannot fully explain the 
increase in glucose transport and the study lacks clarification on the mechanisms 
involved to enhance glucose transport in skeletal muscle. Decrease in fasting blood 
glucose can be due to suppression of gluconeogenesis or/and increased glucose 
disposal in peripheral tissues such as skeletal muscle. The present author has shown 
that CGA inhibited the expression and activity of gluconeogenic G6Pase and hence, 
soleus muscle was next isolated from Lepr
db/db
 mice and treated with CGA followed 
by 2DG transport assay. CGA was shown to stimulate and enhance both basal and 
insulin-mediated glucose transports and thus augmenting glucose utilization in the 
muscle. Additive effect of CGA in insulin-mediated glucose transport suggests that 
CGA may act through a significant pathway which is different from insulin signaling. 
To investigate long-term effect of CGA on glucose uptake in skeletal muscles, we 
isolated the skeletal muscles after 2-week treatment and 2DG transport was performed 
on the muscles. Similarly, glucose uptake was increased in the skeletal muscles after 
long-term treatment with CGA. Consistent with this, immunohistochemistry studies 
revealed that 2-week treatment with CGA increased both expression and translocation 
of GLUT 4, the major insulin-responsive glucose transporter found in peripheral 
tissues. Also, quantitation of GLUT 4 using immunoblotting further supports these 
findings. 
To further support the data, the present author investigated the effect of CGA on 
glucose transport in L6 myotubes and the possible mechanisms to execute its function 
in glucose transport. The results of the present study showed that CGA stimulated 
glucose transport in L6 myotubes in a dose- and time-dependent manner. Optimum 
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increase (~1.5 fold) was observed at the dose of 2 mmol/l after 24-hour incubation 
period, compared to vehicle-treated control. Using non-radioactive glucose transport 
assay, Prakhabar and Doble (2009) demonstrated that CGA caused significant 
increase of glucose transport at micromolar concentration [128]. However, he found 
that micromolar amounts of CGA only mildly stimulated glucose transport (data not 
shown). 
 
4.3 Studies of antilipidemic effects of CGA 
Another striking finding from the present study is the antilipidemic effect of CGA. 
Consumption of coffee induces thermogenesis [196] and most of the researchers 
believe that it was due to the presence of caffeine in coffee as studies have shown that 
caffeine increased energy expenditure and lipid oxidation [197] and lipolysis [198]. 
However, in this study, we showed that CGA inhibits fatty acid synthesis both in vivo 
and in vitro. Free fatty acids are essential blocks for the synthesis of more complex 
lipid molecules such as triacylglycerol or triglyceride [44]. In obesity and T2DM, free 
fatty acids flux is chronically increased and this increase is responsible for the non-
alcoholic hepatic steatosis [44], insulin resistance [45], decrease in skeletal muscle 
glucose disposal [46] and increased hepatic glucose production [47]. CGA inhibited 
fatty acid synthesis in HepG2 hepatocytes and decreased circulating free fatty acids 
level in Lepr
db/db
 mice, which in turn result in decreased triglyceride and cholesterol 
levels. Fat accumulation in liver and hepatoma cells was also reduced by CGA, in line 
with the hypothesis that CGA inhibited lipogenesis in the liver through the inhibition 
of fatty acid synthesis. Owing to these lipid-lowering effects of CGA, a significant 
drop in body weight was observed in Lepr
db/db
 mice treated with CGA, consistent with 
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the previous finding in a human study that consumption of coffee enriched with CGA 
resulted in significant reduction in body weight and fat mass [199]. Possibly, 
restoration of dysregulation of gluconeogenesis, peripheral glucose uptake and insulin 
sensitivity can be partially attributable to the reduction of free fatty acids level in the 
CGA-treated animals. 
 
4.4 Studies of molecular targets that mediate beneficial metabolic 
changes by CGA 
AMPK is a central regulator of cellular metabolism and is sensitive to cellular energy 
changes. Its activation is triggered during energy deprivation and exercise [200]. 
Carey et al (2009) reviewed it as a potential exercise-linked target for “exercise-
mimetics”, an interesting concept of the development of pharmacological agents that 
improve energy expenditure while concomitantly reduce body fat and improve 
metabolic homeostasis [201]. The present author showed that AMPK activation is 
vital in CGA-mediated inhibition of hepatic glucose production and fatty acid 
synthesis. AMPK activation has been shown to inhibit gluconeogenic gene expression 
and hepatic glucose production [31]. Besides, AMPK phosphorylation inactivates 
ACC, leading to inhibition of fatty acids de novo and also cholesterol synthesis while 
increases fatty acid oxidation [202]. His data showed that CGA phosphorylates 
AMPK and ACC, resulting in similar metabolic changes in the liver. Activation of 
AMPK also leads to translocation of GLUT 4 from intracellular membranes to plasma 
membranes, thus increasing glucose transport [203]. Consistent with this, our results 
showed a time- and dose-dependent increase in phosphorylation of AMPK and 
likewise its activity, leading to an increase in the number of GLUT 4 on the plasma 
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membrane of L6 myotubes. However, no changes were observed on the translocation 
of GLUT 1, suggesting that CGA may only affect insulin-sensitive tissues such as 
skeletal muscles, liver and adipocytes. 
CaMKKβ has been reported as an alternative upstream kinase for AMPK besides 
cellular stress (decreased ATP:AMP ratio) and LKB-1 [155]. The present author 
examined whether CGA causes any changes in ATP: AMP ratio but no significant 
changes were observed (data not shown). On the other hand, pretreatment of cells 
with STO-609 also abrogated CGA-inhibited hepatic glucose production and fatty 
acid synthesis, indicating that CAMKK could be the upstream kinase that mediates 
the CGA-activated AMPK. This was further supported by the observation that CGA 
raised intracellular level of free calcium at the same time. He found out later that 
CGA increased expression of CaMKKβ in both L6 myotubes and HepG2 cells, 
strengthening his findings that the upstream target of CGA that activates AMPK is 
CAMKKβ.   
Interestingly, in the in vivo study, pretreatment with compound c did not fully block 
glucose-lowering effect by CGA, suggesting that there could be other mediators being 
activated at the same time. More importantly, after 2-week treatment with CGA, 
inhibitory effect of compound c was significantly decreased in which a doubled dose 
of compound c was required to achieve the inhibitory effect observed initially. This 
suggests that there could be an intermediary molecule which is stimulated by CGA 
and thus indirectly and chronically enhances the activation of AMPK. It is highly 
possible that this molecule could be the anti-diabetic adipokine, adiponectin, which 
has been reported to be decreased in obesity, insulin resistance and T2DM [204]. 
Adiponectin has also been shown to reverse insulin resistance [204], enhance hepatic 
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insulin action [205] and increase fatty acid oxidation [206]. Consistent with this, 
restoration of adiponectin levels in vivo by CGA showed improved glycemia, insulin 
sensitivity and fatty acid metabolism. Moreover, very recently, adiponectin has been 
demonstrated to activate AMPK via CAMKK [207]. Therefore, restoration of 
adiponectin in vivo by CGA could have enhanced the activation of AMPK and 
resulted in the above-mentioned beneficial metabolic alterations (Figure 4.4). 
On the other hand, in accord with the earlier report that CGA did not show any 
significant effect on the expression of PI3K [128], the present author further 
demonstrated that CGA did not activate PI3K as no significant association was 
observed between p85 subunit of PI3K and IRS-1, suggesting a negative role of CGA 
on phosphorylation of IRS. However, to our surprise, he observed phosphorylation of 
Akt in the absence of PI3K activation. In rat heart, phosphorylation of Akt has been 
shown to phosphorylate AMPKα1 subunit at Ser 485/491 and hence interfering with 
the LKB-1-mediated activation of AMPK at its Thr 172 residue [208]. This indicates 
that Akt negatively influenced AMPK activation and activity. Other groups of 
researchers have reported that several stimuli such as adiponectin [209] and VEGF 
[210], elicited parallel activation of both AMPK and Akt. Likewise, they proposed the 
upstream nature of AMPK, by which Akt is activated by the phosphorylation of 
AMPK at Thr 172. This is highly notable as both insulin-dependent and AMPK-
dependent pathways converge to activate Akt substrate of 160 kDa (AS160) and Akt 
may be the point of convergence instead of AS160 (Figure 4.4). The present results 
seem to favour the latter but subsequent studies to determine the activities of AMPK 
and Akt are required to support the occurrence of this phenomenon. 
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Several studies have reported that AMPK activation by the well-known AMPK 
activator, AICAR, led to cell cycle arrest which involved accumulation of tumor 
suppressor protein p53 [211]. However, he did not detect any significant changes on 
cell viability and cell cycle of L6 myotubes even after 24 hours of incubation in the 
presence of 2 mmol/l CGA. This might be due to the parallel activation of pro-
survival Akt, as Akt regulates apoptosis through direct targets such as Bad, caspase 9, 
the Forkhead family of transcription factors and the NF-κB regulator, IKK [212]. 
More importantly, the data eliminates the possibility that the increase in glucose 
transport might be due to the effect of CGA on cell proliferation.  
4.5 Possible cytotoxic effect of CGA 
From Figure 3.3.9, CGA started to show cytotoxic effect on L6 myotubes at a dose of 
≥4mM. This may certainly affect its clinical or practical significance in managing 
T2DM. However, if the figure is studied more thoroughly, it is evident that CGA 
(≥4mM) did not result in more than 20% cell death. In other words, CGA may not be 
statistically or clinically cytotoxic at doses up to 10mM. Besides, even for the widely 
used antidiabetic metformin, at a dose of 10mM, it caused ≈10% cell death in the 
same cellular model (data not shown). In addition, the present author's in vivo toxicity 
study showed that the LD50 of CGA in  BALB/c mice is more than 3.5kg/g (data not 
shown), which is ten times higher than our studied dose. Therefore, it is very unlikely 
that CGA would cause toxicity in vivo and compromising its beneficial effects on 




    
4.6 VA vs CGA vs Met 
 
At  this point of studies, although both VA and CGA showed hypoglycemic effects in 
different manners, the present author was unable to conclude whether VA or CGA can 
be as effective as metformin for the treatment of T2DM. First, as discussed in Section 
4.1, VA contains cytotoxic active constituents which theirs effects are unknown in 
diabetic model. Second, the oral bioavailability of CGA remains unclear to date 
(please refer to Chapter 5).  
Besides CGA, the most abundant components in VA, di-CQAs, may contribute to its 
glucose-lowering effect as well. To investigate about this, the present author 
examined the effects of one of the di-CQA isoforms, 1.5-dicaffeoylquinic acid, on 
glucose transport in L6 myotubes (details please see Chapter 5 and Appendix 4). We 
observed a mild stimulation using up to 100μM 1,5-dicaffeoylquinic acid.  
At a dose of 100 mg/kg (approximate equivalent dose of CGA in 400 mg/kg VA), 
CGA still resulted in similar glucose-lowering effects pre- and post-glucose loading if 
it was administrated intraperitoneally (higher AUC if compared to 250 mg/kg) [data 
not shown]. However, if it was fed orally, the present author did not observed 
glucose-lowering effects which are as strong as those in VA, if compared to DC. He 
believe that it could be due to I) the low oral bioavailability of CGA, II) di-CQAs in 
VA which could have better oral bioavailability, III) other active constituents in VA 
that may be able to protect CGA from undergoing degradation or modification or IV) 
active constituents in VA that may be able to enhance CGA absorption. Further works 
are needed to explain these observations. 
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Figure 4.4. Cross-talk between insulin signalling & insulin-independent pathways and 












    
5 Conclusions and Future Perspectives 
VA shows anti-hyperglycemic effect in the single-dose STZ-induced diabetic rat 
model. This effect was most possibly mediated through inhibition of key hepatic 
G6Pase and increase in expression and translocation of GLUT 4 in skeletal muscle. 
Previous studies reported that VA increased insulin secretion. However, due to the 
nature of our diabetic model, the massive destruction of pancreatic β-cells may mask 
the stimulatory effect. Further studies are required to confirm whether VA increases 
insulin secretion. VA also showed positive modulation of the lipid profile and 
antioxidant defense. All these biological effects may be attributed to the polyphenols 
in the extract, especially caffeoyl-quinic acids (CQA) and its isomers.  
Owing to the abundance of caffeoyl-quinic acids and its isomers in VA extract, the 
present author decided to choose one of the most common caffeoyl-quinics, CGA, to 
study its potential antidiabetic effects.  The present study demonstrated for the first 
time that CGA regulates glucose and lipid metabolism via the activation of AMPK. 
CGA inhibited hepatic G6Pase expression and activity, attenuated hepatic steatosis, 
improved lipid profiles and skeletal muscle glucose uptake, which in turn improve 
fasting glucose levels, glucose tolerance, insulin sensitivity and dyslipidemia. All 
these suggest that CGA could be the main component that contributes to the beneficial 
effect of coffee and also the paradoxical effect of coffee in T2DM subjects. 
To date, the bioavailability of intact CGA remains unresolved. One group of 
researchers reported that large amount of CQAs, di-CQAs and their isomers were 
found in human plasma and urine after coffee consumption, indicating its high 
absorption and bioavailability [213, 214]. However, CQAs have not been detected 
after coffee consumption in other studies [215, 216], consistent with a very recent 
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study which demonstrated that most of the CQAs found in plasma were mainly 
reduced and/or sulfated and/or methylated [217]. In another study that measured intact 
CGA in plasma after 1 to 3 hours after coffee ingestion, a very low amount of CQAs 
(10-40nm) was detected [218]. On the other hand, a study in rats has shown that CGA 
was absorbed intact in stomach [219] while another group observed that CGA was 
mostly absorbed as phenolic acids after hydrolysis by microbial enzymes [220].  Our 
preliminary study (in which CGA was fed orally to Lepr
db/db
 mice) seems to favour 
the fact of low bioavailability of CGA. Compared to ip administration, oral gavage of 
CGA during an OGTT resulted in higher AUCglucose and diminished its hypoglycemic 
effect before the glucose challenge as shown in Appendix 3. Further investigations are 
needed to clarify this phenomenon. Also, a study on the bioavailability of CGA 
should be performed following ingestion of CGA instead of coffee.  
The present author has also tested the effect of one of the di-CQAs, known as 1,5-
dicaffeoylquinic acid (1,5DCQA), on glucose transport in L6 myotubes. Surprisingly, 
he observed a mild stimulation using concentrations of up to 100μM (Appendix 4). 
Further works are needed to investigate its effect(s) on glucose metabolism. 
Although it is premature at this stage to conclude that CGA can be used as a 
therapeutic tool for T2DM, from the studies discussed above, it is evident that the 
impact of CGA on carbohydrate or glucose metabolism is extensive. This is highly 
significant considering that obesity is positively correlated to metabolic diseases like 
diabetes mellitus and increased intakes of CGA-rich foods not only are beneficial to 
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7 List of Appendices 
 
Appendix 1.  Criteria for the diagnosis of diabetes mellitus 






Fasting blood glucose 
mg/dl <100 100-125 - ≥126 
mmol/l <5.6 5.6-6.9 - ≥7.0 
 
2-hr post OGTT 
mg/dl <140 - 140-199 ≥200 
mmol/l <7.8 - 7.8-11.0 ≥11.1 
 











    
Appendix 2.  Number of individuals with diabetes mellitus [by World Health 
Organization (WHO) Regions] 
Region 2000 2030 
African region 7,020,000 18,234,000 
Eastern Mediterranean 15,188,000 42,600,000 
Region of the Americas 33,016,000 66,812,000 
European 33,332,000 47,973,000 
Southeast Asia 46,903,000 119,541,000 
Western Pacific 35,771,000 71,050,100 
Total 171,230,000 366,210,100 
 









    
Appendix 3.  Acute effects of oral gavage of CGA on fasting blood glucose, 
compared  to i.p. CGA 
 
 
Oral glucose tolerance test was performed in 6-hour fasted Lepr
db/db
 mice. Blood 
samples were collected from the tail vein for fasting glucose measurement before 
treatments (vehicle, ip 250 mg/kg CGA, oral gavage 250 mg/kg CGA). Ten minutes 
after the treatments, blood samples were collected again followed by oral gavaging of 
2 g/kg glucose. Blood samples were collected 15, 30, 60 and 120 minutes after the 
glucose challenge.  
Data were expressed as the means ± SE of three independent experiments. 









    
Appendix 4.  Effect of 1,5 DCQA on glucose transport in L6 myotubes 
 
 
L6 myotubes were incubated with incremental concentrations of 1,5DCQA for 24 
hours. 2-deoxyglucose uptake was measure over a 30-minute period, using liquid 
scintillation counter. Readings are expressed as percentage increase over basal uptake 
of cells incubated with vehicle.  
Data were expressed as the means ± SE of three independent experiments. *P<0.05, 
**P<0.01 compared with vehicle-treated control. 
 
 
 
